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µCi      Microcuries  
µg       Microgramm 
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µM      Micromolar 
3D7        Plasmodium falciparum clone 3D7 
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Cfu      Colonies forming unit 
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g/l       gram per liter 
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GSH       Glutathion 
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ICAM       Intercellular adhesion molecule 
IFA       Indirect immunofluorescence assay 
IFN       Interferon 
Ig       Immunoglobulin 
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M       Molar 
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NaN3       Sodium azide 
NEB       New England Biolabs 
nt       Nucleotide 
NTP      Nucleoside triphosphate 
O/N       Over night 
OD       Optical density 
p       Pico 
P. falciparum     Plasmodium falciparum 
PAGE      Polyacrylamide gel electrophoresis 
PBS       Phosphate buffered saline 
PCR       Polymerase chain reaction 
PEG       Polyethylene glycol  
PFA       Paraformaldehyde 
PfCRT  P. falciparum Chloroquine Resistance 
Transporter (Protein) 
PfEMP-1  Plasmodium  falciparum erythrocyte 
membrane protein 1 
pfmdr-1      P. falciparum multidrug resistance gene 1 
pH       „potentia hydrogenii“ 
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PRBC      P. falciparum infected red blood cell 
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RNase A      Ribonuclease A 
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1. INTRODUCTION 
1.1 Malaria  
1.1.1 History of malaria  
Malaria, derived from the latin Malus aria or the Italian mala aria both meaning 
bad air, was so named because the disease was thought to be caused by the 
breathing of bad air from the swamps.  Its other name was swamp fever. Probably 
one of the oldest known diseases, malaria remains one of the most widespread 
illness with nearly 40% of the world population at risk (Snow et al., 2005). These 
areas are limited to the tropical and subtropical regions, most common between the 
latitudes of 23.5° North and 23.5° South (Fig.1). Ea ch year 300 to 500 million people 
contract malaria with a death toll estimated at 1.5 to 2 million and more than 90 % of 
the infections happen in Africa (Snow et al., 2005). The highest risk groups are 
children under 5 years old, pregnant women and none-immune travellers: an 
estimated 50 to 70 million Western travellers are exposed to malaria infection 
annually (Schlagenhauf, 2004). Beyond the clinical issues, malaria also poses an 
economic problem as the disability provoked influences negatively the productivity at 
work (Sachs and Malaney, 2002).  
In 1880, Alphonse Laveran who won the Nobel Prize for his major contribution 
in the field of malaria discovered the parasite responsible for malaria. The causative 
agent of malaria is the unicellular eukaryotic parasite of the protozoa group from the 
genus Plasmodium, (phylum Apicomplexa, class Sporozoa, order Coccidida, genus 
Haemosporidiae, and family Plasmodiidae). The four species affecting humans are 
Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium 
malariae. These parasites give rise to different forms of malaria: Malaria tropica (P. 
falciparum), Malaria tertiana (P .vivax, P. ovale) and Malaria quartana (P. malariae). 
P. falciparum is the most serious form of malaria, with shorter prepatent periods (the 
period between infection and appearance of parasites in the blood) and higher 
parasitemia. The parasites of P. falciparum multiply very rapidly because P. 
falciparum invades red cells of all ages, whereas P. vivax and P. ovale prefer 
invading younger red cells, the reticulocytes, while P. malariae seeks mature red 
cells (Mons, 1990). 
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Sir Ronald Ross, another major contributor to the understanding of malaria 
transmission, observed that the parasites are spread by the female Anopheles 
mosquitoes (phylum Arthropoda, class Insecta, order Diptera, genus Nematocera, 
and family Culicidae). The mosquitos become infected upon feeding on a malaria-
infected person. These infected mosquitos then go on to infect further hosts upon 
blood feeding. Of the approximately 380 known Anopheles species only 60 can 
function as a vector for Plasmodium spp. All Plasmodium parasites seem capable of 
adapting to any non-refractory Anopheline mosquito, given sufficient time and 
contact. Sporogony within the mosquito is governed by environmental temperature as 
Anopheline mosquitoes are poikilotherms. The mosquitoes live at optimal 
temperatures between 18°C and 33°C (Fang and McCutcha n, 2002).  
 
 
Fig 1.1: Distribution of malaria in the world from 1946 to 1994 (Sachs and Malaney, 2002) 
 
 
 
1.1.2 The Plasmodium life cycle  
Knowledge of the life cycle of Plasmodium is a key to understanding the 
clinical features, the treatment, and the research on malaria. Plasmodium is an 
obligate endoparasite and has a complex life cycle. The parasite has two major 
stages: the asexual stage, called schizogony, which takes place in the human host 
and the sexual stage, called sporogony, which takes place into the Anopheles 
mosquito. The life cycle is summarized in the Fig 2.  
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During its blood feeding between dusk and dawn, the female anopheles 
mosquito injects sporozoites from its saliva into the skin of the human host. Males 
subsist on nectar; therefore they do not have a blood meal. Those sporozoites, after 
approximately half an hour, reach the liver where they infect hepatocytes and therein 
proliferate to give thousands of merozoites for each single hepatocyte. This step, 
called the exoerythrocytic cycle, can last for 9-16 days. The parasites from P.vivax 
and P.ovale can remain dormant in the liver as hypnozoites, leading to recurrent 
infection or relapse. The merozoites rupture from the hepatocytes and are delivered 
to the blood stream where they invade erythrocytes. During this erythrocytic stage, 
the merozoites develop into ring trophozoites, mature trophozoites and then into 
schizonts which then release 8 to 32 merozoites to further infect other erythrocytes. 
After some cycles, some merozoites, after the invasion of erythrocytes, differentiate 
into gametocytes. The gametocytes are ingested by female Anopheles mosquito 
during a blood feeding.  
The development of the parasite in the mosquito is known as the sporogonic 
cycle. Whilst in the stomach of the mosquito, the microgamete fertilizes the female 
macrogamete, generating a zygote. The zygote in turn becomes motile and 
elongated (ookinete) and invades the midgut wall of the mosquito, where it develops 
into an oocyst. Within the oocyst, many sporozoites are formed by mitotic division. 
The oocyte grows and ruptures, thereby releasing infective sporozoites. After the cyst 
ruptures, the sporozoites escape into the haemocoele and migrate to and penetrate 
into the salivary gland cells, where they remain for up to 59 days. Inoculation of these 
sporozoites into a new human host perpetuates the malaria life cycle. In P. 
falciparum, erythrocytic schizogony takes 48 h and the sporogony takes 10-12 days.  
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Fig 1.2: Life cycle of Plasmodium falciparum. The malaria parasite life cycle involves two hosts.  
During a blood feeding, a malaria-infected female Anopheles mosquito inoculates sporozoites 
into the human host .  Sporozoites infect liver cells and mature into schizonts , which 
rupture and release merozoites .  (Of note, in P. vivax and P. ovale a dormant stage 
[hypnozoites] can persist in the liver and cause relapses by invading the bloodstream weeks, or 
even years later.)  After this initial replication in the liver (exo-erythrocytic schizogony ), the 
parasites undergo asexual multiplication in the erythrocytes (erythrocytic schizogony ).  
Merozoites infect red blood cells .  The ring stage trophozoites mature into schizonts, which 
rupture releasing merozoites .  Some parasites differentiate into sexual erythrocytic stages 
(gametocytes) .  Blood stage parasites are responsible for the clinical manifestations of the 
disease. The gametocytes, male (microgametocytes) and female (macrogametocytes), are 
ingested by an Anopheles mosquito during a blood meal .  The parasites’ multiplication in the 
mosquito is known as the sporogonic cycle .  While in the mosquito's stomach, the 
microgametes penetrate the macrogametes generating zygotes .  The zygotes in turn become 
motile and elongated (ookinetes)  which invade the midgut wall of the mosquito where they 
develop into oocysts .  The oocysts grow, rupture, and release sporozoites , which make their 
way to the mosquito's salivary glands.  Inoculation of the sporozoites into a new human host 
perpetuates the malaria life cycle   (National Center for Infectious Diseases, Division of Parasitic 
Diseases) 
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1.1.3 Clinical features and pathogenicity 
  
1.1.3.1 Clinical symptoms 
Fever is the most characteristic symptom of malaria. Other common symptoms 
include chills, headache, myalgias, nausea, and vomiting. Diarrhea, abdominal pain, 
and coughing are occasionally observed. As the disease progresses, some patients 
may develop the classic malaria paroxysm with bouts of illness alternating with 
symptom-free periods. The malaria paroxysm comprises three successive stages. 
The first is a 15-to-60 min cold stage characterized by shivering and a feeling of cold. 
Next comes the 2-to-6 h hot stage, in which there is fever, sometimes reaching 41°C, 
flushed, dry skin, and often headache, nausea, and vomiting. Finally, there is the 2-
to-4 h sweating stage during which the fever drops rapidly and the patient sweats. In 
all types of malaria the periodic febrile response is caused by rupture of erythrocytic 
mature schizonts. In P. vivax and P. ovale malaria, a brood of schizonts matures 
every 48 hr, so the periodicity of fever is tertian (“tertian malaria”), whereas in P. 
malariae disease, fever occurs every 72 h (“quartan malaria”). The fever in falciparum 
malaria may occur every 48 hr, but is usually irregular, showing no distinct periodicity. 
These classic fever patterns are usually not seen early in the course of malaria, and 
therefore the absence of periodic, synchronized fevers does not rule out a diagnosis 
of malaria. (Baron, 1996).         
 If the diagnosis of malaria is missed or delayed, especially in P. falciparum 
infections, potentially fatal complicated malaria may develop in the so called severe 
malaria. The major forms syndromes of severe malaria are cerebral malaria, caused 
by obstruction of small vessels of the brain by sequestered parasites, and severe 
anemia caused by the destruction of the erythrocytes. In cerebral malaria the clinical 
features are: impaired consciousness, convulsions and long-term neurological deficit. 
In severe anemia is the impaired consciousness frequent, other symptoms include 
respiratory distress and shock.        
 Other complications in both forms include: hyperparasitemia (more than 3 to 5 
percent of the erythrocytes parasitized), severe hypoglycemia, lactic acidosis, 
prolonged hyperthermia, pulmonary, cardiac, hepatic, or renal dysfunction, seizures, 
spontaneous bleeding, or high-output diarrhoea or vomiting, gram-negative sepsis, 
aspiration pneumonia and splenic rupture. These manifestations are associated with 
poor prognosis. Persons at increased risk of severe disease from malaria include 
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older persons, children, pregnant women, non-immune persons and those with 
underlying chronic illness.  
 
1.1.3.2 The pathogenic basis of malaria 
The symptoms of malaria begin with the invasion of the erythrocytes by the 
merozoites and the rupture of host cells and the release of parasite products into the 
blood stream. The fever is caused by the release of malaria toxins and antigens, and 
the release of pro-inflammatory cytokines such as TNF alpha and Interleukin 
(Kwiatkowski et al., 1989). Those pro-inflammatory cytokines are also involved in 
cerebral malaria (Sanni et al., 2004;Troye-Blomberg et al., 1999 ). 
Anemia is caused by the destruction of erythrocytes during schizogony. The 
asexual replication leads to tremendous amplification with parasite burdens that may 
reach 1012 parasites per patient (Arav-Boger and Shapiro, 2005). Anemia is also 
caused by the absorption of antigen on non-parasitized erythrocytes with 
complement-mediated lysis, suppression of hematopoiesis by cytokines (McDevitt et 
al., 2004), and the therapy-associated hemolysis induced by medications in G6PD 
deficiency.  
Hypoglycemia is common in malaria; as malaria parasitized erythrocytes utilize 
glucose 75 times faster than uninfected cells but there is no direct correlation 
between hypoglycemia and parasitaemia (Elased and Playfair, 1996). In addition, 
treatment with quinine and quinidine stimulate insulin secretion, reducing blood 
glucose (Davis et al., 2002). 
Cerebral malaria is caused as previously mentioned by obstruction of small 
vessels of the brain by sequestered parasites (Smith et al., 2000).. Parasites 
sequester themselves also in the placenta, the lung, the liver, the kidney and 
subcutaneous tissues (Gamain et al., 2001). The surface changes of the infected 
erythrocytes allowing this sequestration are parasite encoded adhesions that are the 
contact point with the host cells (Luse and Miller, 1971; Smith et al., 2001). A single 
protein PfEMP1, expressed at the surface of the infected erythrocyte mediates 
adherence to many endothelial receptors (Baruch et al., 1997). PfEMP1 is the 
product of the var gene family that is involved in antigenic variation thus playing a 
major role in the pathogenesis of malaria (Newbold et al., 1997). The extracellular 
region of PfEMP1 possesses multiple adhesion domains which allow binding to a 
broad range of endothelial cell receptors (Smith et al., 2000), inlcuding CSA, ICAM1, 
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and CD36 for the placenta, the brain and the vascular endothelium (Baruch et al., 
1997).  
 
1.1.4 Chemotherapy  
 
1.1.4.1 Mode of action of antimalarial drugs 
 
1.1.4.1.1 Quinolines 
Discovered just before World War II in 1934, chloroquine (CQ) has been for 
decades a cheap, efficient, safe, fully synthetic antimalarial drug. The emergence of 
the chloroquine resistance (CQR) in the early 1960s and its spread worldwide has 
seriously compromised its use nowadays for treatment against malaria (Farooq and 
Mahajan, 2004).        
 Chloroquine is thought to exert its antimalarial effect by binding to toxic haem, 
thereby preventing the detoxification of haem. Haem is released during proteolysis of 
haemoglobin and detoxified by crystallisation in the parasites acidic food vacuole 
(Sullivan et al., 1996). Other heme detoxification pathways that had been considered 
include peroxidative degradation (Loria et al., 1999; Zhang et al., 1999), and 
glutathione-dependent degradation (Zhang et al., 1999; Ginsburg et al., 1998). The 
heme-chloroquine complex strongly promotes the peroxidative cleavage of 
phospholipid membrane (Sugioka, 1991). This mode of action is thought to be similar 
for other quinolines (Zhang et al., 1999). 
 
1.1.4.1.2 Folic Acid Antagonists 
The most widely used antimalarial drugs of this type include pyrimethamine, 
proguanil, sulfadoxine and dapsone.  They have the best defined molecular targets, 
namely the enzymes dihydrofolate reductase (DHFR) and dihydropteroate synthase 
(DHPS) respectively inhibited by pyrimethamine, proguanil and sulfadoxine, dapsone, 
which function in the folate metabolic. The products of this pathway, reduced folate 
cofactors, are essential for DNA synthesis and the metabolism of certain amino acids 
(Hyde, 2005). 
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1.1.4.1.3 Hydroxynaphthoquinones 
Atovaquone inhibits respiration and collapses the mitochondrial membrane 
potential in live intact malaria parasites by inhibiting the cytochrome bc1 complex 
(Srivastava et al., 1997; Srivastava et al., 1999). 
 
1.1.4.1.4 Artemisinins  
Artemisinins are extracted from sweet wormwood (Artemisia annua) and are 
the most potent antimalarials available, rapidly killing all asexual stages of 
Plasmodium falciparum. Artemisinins remain the last hope for the containment of 
malaria. Artemisinins are sesquiterpene lactones, which possibly act by targeting the 
SERCA of the parasite (Eckstein-Ludwig et al., 2003). The affordability in terms of 
cost of the drug is still its limitation but the recent discovery that the peroxide bridge is 
the key of its mode of action and the  synthesis of a peroxide antimalarial  is 
promising (Vennerstrom et al., 2004). 
 
1.1.4.2 Mechanism of resistance 
 
1.1.4.2.1 Chloroquine  
Over the past years many different theories regarding chloroquine resistance 
have been proposed. Presently three main theories are still debated:  
1) The pH. CQ, by virtue of its weak base properties, concentrates in the acidic 
compartment(s) of the intraerythrocytic parasite. Drug accumulation is essential for it 
to exert its pharmacological activity (Bray et al., 1998). Drug resistance has been 
thought to result from insufficient acidification of drug-accumulating organelle(s). The 
difference in pH between the CQ sensitive and CQ resistant strains, allowing 
differential accumulation of CQ could explain the resistance (Ginsburg and Stein, 
1991). Nevertheless studies on the vacuolar pH of CQR and CQ sensitive are very 
controversial (Krogstad et al., 1992; Dzekunov et al., 2000) 
2) The binding affinity of CQ to heme. CQ resistant strains of P. falciparum have 
evolved a mechanism to reduce the saturable uptake and this saturable 
accumulation of chloroquine is due to intracellular binding to ferriprotoporphyrin IX 
(Bray et al., 1999). 
3) The efflux of CQ. Chloroquine-resistant P. falciparum accumulate significantly less 
chloroquine than susceptible parasites, and this is thought to be the basis of their 
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resistance. The resistant parasite has now been found to release chloroquine 40 to 
50 times more rapidly than the susceptible parasite, although their initial rates of 
chloroquine accumulation are the same (Krogstad et al., 1987). Verapamil and two 
other calcium channel blockers, as well as vinblastine and daunomycin, each slowed 
the release and increased the accumulation of chloroquine by resistant (but not 
susceptible) P.falciparum. These results suggest that a higher rate of chloroquine 
efflux explains the lower chloroquine accumulation, and thus the resistance observed 
in resistant P. falciparum (Krogstad et al., 1987). Recently, compelling biochemical 
evidences further strongly support the theory of a CQ efflux mechanism (Sanchez et 
al., 2004) linked to the pfcrt gene product, PfCRT, a food vacuoler membrane protein 
that has several conserved amino cid substitutions in CQR parasites (Naude et al., 
2005; Fidock et al., 2000). 
 
 
Fig. 1.3: Global status of resistance to chloroquine and sulfadoxine/pyrimethamine, the two 
most widely used antimalarial drugs (Ridley, 2002). 
 
 
1.1.4.2.2 Other antimalarials 
Apart from CQ where the mechanism of resistance is still unclear, most of the 
other antimalarials have known mechanisms of resistance which arise from defined 
genetic mutation(s) of the drug target. Mutations in P. falciparum cytochrome b that 
are associated with atovaquone resistance are located at the Y268 residue 
(Korsinczky et al., 2000, Peters et al., 2002).  A point mutation N108 in dihydrofolate 
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reductase-thymidylate synthase confers resistance to pyrimethamine (Peterson et al., 
1988) while mutations in the dihydroopterotate synthase determines sulfadoxine 
resistance (Wang et al., 1997;Triglia et al., 1998). The N1042D mutation on the 
PfMDR1 was shown to significantly contribute to quinine resistance and the triple 
mutations S1034C/N1042D/D1246Y found to enhance parasite susceptibility to 
mefloquine, halofantrine and artemisinin (Sidhu et al., 2005). 
   
 
1.2 The calcium homeostasis  
  
1.2.1 General overview 
Ca2+ is a highly versatile intracellular signal that operates over a wide temporal 
range to regulate many different cellular processes (Lodish H, 2000). An extensive 
Ca2+-signalling toolkit exists to assemble signalling systems with very different spatial 
and temporal dynamics. Rapid highly localized Ca2+ spikes regulate fast responses, 
while slower responses are controlled by repetitive global Ca2+ transients or 
intracellular Ca2+ waves. Ca2+ also has a direct role in controlling the expression 
patterns of its signalling systems that are constantly being remodelled in both health 
and disease (Berridge et al., 2003).    
The calcium concentrations outside the cells are 10 000 times higher than free 
intracellular Ca2+, (Ca2+)i, the physiologically active form of calcium (Rasmussen and 
Rasmussen, 1990). The level of (Ca2+)i is regulated and maintained as low as ~100 
nM through the concerted action of a number of binding proteins and ion exchange 
mechanisms. Soluble proteins, such as calmodulin, contribute to the buffering of cell 
Ca2+, but membrane-intrinsic transporting proteins are more important. Ca2+ signal 
transduction is based on increases in free cytosolic Ca2+ concentration. This increase 
in Ca2+ can originate from the extracellular space or be released from intracellular 
stores. Extracellular Ca2+ enters the cell through various types of plasma-membrane 
Ca2+ channels, and leaves the cell via pumps and Na+/Ca2+ exchangers (Kasai and 
Muto, 1990; Balasubramanyam et al., 1993). The endoplasmic reticulum (ER) is a 
major site for sequestered Ca2+ ions. Ca2+ is accumulated into intracellular stores by 
means of Ca2+ pumps and released by inositol 1,4,5-trisphosphate (IP3) via IP3 
receptors and by cyclic adenosine diphosphate ribose (cADPr) via ryanodine 
receptors (Clapham, 1995, Clapham, 1995, Putney, 1999). A connection has been 
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demonstrated between the filling status of the intracellular calcium stores and the 
plasma membrane calcium channel activity (Putney, 1990).    
 
 
 
 
 
 
 
 
 
  
 
 
Fig. 1.4:  The mechanism of Ca2+ transport in a eucaryotic cell. 
(Korkiamäki, 2002). Extracellular Ca2+ enters the cell through plasma 
membrane Ca2+ channels and leaves the cell using Ca2+ pumps and 
Na+ / Ca2+ exchangers. Endoplasmic reticulum (ER) is a major site for 
sequestered Ca2+ ions. Ca2+ is accumulates in intracellular stores by 
means of Ca2+ pumps and released by inositol 1,4,5-triphosphate 
(IP+) via IP3 receptors (IP3R) and by cycli adenosine diphosphate 
ribose (cADPr) via ryonodine receptors (RyR). Store-opened calcium 
channels (SOCs) open in responde to depletion of the (ER) Ca2+ 
stores. Calcium influx factor (CIF) has postulated to mediate the signal 
from IP3R to the plasma membrane store-operated calcium channels 
(SOCs). 
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1.2.2 In P. falciparum 
 
The calcium ion Ca2+ is also a major signaling molecule in a diverse range of 
human parasitic protozoa, such as Trypanosoma spp, Leishmania spp, Plasmodium 
spp, Toxoplasma gondii, Giardia lamblia and Trichomonas vaginalis (Vercesi et al., 
1997;Arrizabalaga et al., 2004). Ca2+ is critical for the invasion of these intracellular 
parasites, and its cytosolic concentration is regulated by the concerted operation of 
several transporters present in the plasma membrane, endoplasmic reticulum, 
mitochondria and acidocalcisomes. Recent findings have shed the light on the 
function of these transporters, the roles that they play in cellular metabolism and their 
potential use for targeting them for in therapies (Moreno and Docampo, 2003). 
 The first evidence that calcium is essential for continuous growth of P. 
falciparum in vitro was observed in the 80s (Divo et al., 1985). Later Calcium channel 
blockers were found to suppress parasite growth in vitro (Matsumoto et al., 1987) and 
artemisinin, a potent antimalarial, inhibits the SERCA of P. falciparum (Mercereau-
Puijalon and Fandeur, 2003; Eckstein-Ludwig et al, 2003). Moreover calmodulin, a 
calcium-dependent modulator protein, was shown to be indispensable for growth of 
erythrocytic stages of the human malaria parasite, P.falciparum. When the potent 
calmodulin antagonists W7, trifluoperazine (TFP) or R24571, were added to cultures 
of P. falciparum they inhibited invasion of erythrocytes by merozoites, and maturation 
of schizonts (Scheibel et al., 1987).  
  
Calcium is involved in various processes in the parasite including 
gametogenesis, invasion of hepatocytes and erythrocytes, cytoadherence and 
metabolic processes. The induction mechanism of gamete formation 
(gametogenesis) in a rodent malaria parasite is influenced by Ca2+ levels. Ca2+ 
release inhibition using acid 8-(diethylamino) octyl ester (TMB-8, a Ca2+ release 
inhibitor) blocked formation of male gametes by inhibiting DNA synthesis (Kawamoto 
et al., 1993). Recent genetic evidence has revealed isoform-specific functions for 
calcium-dependent protein kinases CDPK and Ca2+ that are essential for P. berghei 
gametogenesis (Billker et al., 2004). Invasion of hepatocytes and erythrocytes is also 
a Ca2+dependent process. It has been proposed that the P. falciparum 
circumsporozoite protein (CS) central region plays a role in the invasion of 
hepatocytes, as a specific Ca2+ macroligand, a critical functions during attachment, 
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invasion, and development of the malaria parasite in the hepatic cell (Verdini et al., 
1991). Circumsporozoite protein (CS), the primary protein antigen found on the 
surface of sporozoites, binds to the basolateral domain, the heparin sulphate 
proteoglycans, of hepatocytes (Miller et al., 2002). 
Ca2+ was also shown to be indispensable for the invasion of erythrocytes by 
merozoites (Wasserman et al., 1982). Indeed inclusion of ethyleneglycolbis (beta-
amino-ethylether) N,N'-tetra-acetic acid (EGTA) caused blocking of the asexual cell 
cycle of the parasite in two sites, the first blockage occurring between 20 and 26 h 
after invasion of the erythrocyte (Wasserman et al., 1982). This leads to 
morphologically abnormal parasites arrested in the mature trophozoite stage of the 
cycle. The second site of inhibition was probably one of the steps in the process of 
invasion of the erythrocyte by the merozoite (Wasserman et al., 1982). When 1 mM 
EGTA was added 24--30 h after the culture was synchronized and the cell cycle of 
the parasite continued without any interference in the normal maturation until the 
development of schizonts and release of merozoites into the medium. However, 
reinvasion of fresh erythrocytes by these merozoites was impeded. The inhibition of 
reinvasion caused by EGTA was overcome by the addition of an excess of Ca2+ 
(Wasserman et al., 1982). In another study Wassermann et al. (Wasserman et al., 
1990) showed that the Ca2+ concentration increased about 10 times in recently 
infected erythrocytes and conclude that a calcium influx into erythrocytes might 
precede or accompany merozoite invasion, which may trigger a series of molecular 
events, including phosphorylation and dephosphorylation of cystoskeletal proteins.  
Serine proteases play crucial roles in erythrocyte invasion by merozoites of the 
malaria parasite (Blackman et al., 1993). The Plasmodium falciparum subtilisin-like 
protease-1 (PfSUB-1) is synthesized during maturation of the intraerythrocytic 
parasite and accumulates in a set of merozoite secretory organelles, suggesting that 
it may play a role in host cell invasion or post-invasion events. It requires high levels 
of calcium for optimum activity and possesses at least 3 potential calcium binding 
sites (Withers-Martinez et al., 2002). PfSUB2, another calcium-dependent serine 
protease could be responsible for the late MSP1 maturation step (Barale et al., 
1999). 
The phenomenon of cytoadherence is also a Ca2+-related process. In vitro 
studies have shown that pH and also high concentrations of Ca2+ enhance binding of 
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infected erythrocytes to amelanotic melanoma cells, the "target" cells in an in vitro 
cytoadherence assay (Smith et al., 1992).  
Moreover, Ca2+ levels are further important in various metabolic processes. 
Bloodstage malaria parasites require proteolytic activity for key processes as 
hemoglobin degradation and merozoite escape from red blood cells (RBCs). P. 
chabaudi and P. falciparum have a cytoplasmic dependent cysteine-protease activity 
elicited by Ca2+ (Farias et al., 2005). Ca2+ plays a role in the signalling pathway of 
Plasmodium with the cAMP as second messengers in melatonin-dependent 
regulation of P. falciparum cell cycle (Beraldo et al., 2005). Calcium dependent 
protein kinases are  
found in various subcellular locations, suggesting an involvement in multiple signal 
transduction pathways (Moskes et al., 2004). 
 
Normal mammalian erythrocytes lack intracellular Ca2+ stores and maintain a 
low cytosolic Ca2+ concentration of between 20 and 30 nM (Lew et al., 1982) through 
the action of a plasma membrane Ca2+ pump (a P-type ATPase) (Carafoli, 1987) 
which extrudes Ca2+ into the blood plasma where the Ca2+ concentration is 1-2 mM 
(Kirk, 2001). The high Ca2+ concentration in the infected erythrocyte is preferentially 
located inside an area, corresponding to the position and size of the parasite. In 
contrast, the Ca2+ concentration outside this area is not higher than that in normal red 
blood cells. This higher Ca2+ content becomes significant at the end of the ring stage. 
The concentration measured in 36 h schizonts reaches two times that measured in 
uninfected erythrocytes, and it peaks to four times control values in late schizonts 
(Adovelande et al., 1993). The cytosolic Ca2+ concentration rises from 40 nM in the 
early trophozoite stage to 110-125 nM in the late schizonts (Garcia et al., 1996).  
A serie of recent studies on a range of different plasmodial species has 
provided evidence for the presence of a number of discrete intracellular Ca2+ pools 
within the intracellular parasite. One, presumed to be localized to the parasite’s 
endoplasmic reticulum, is reportedly discharged by inhibitors of the endoplasmic 
reticulum Ca2+ pump (e.g., thapsigargin, 2,5-di-(tert-butyl)-1,4-hydroquinone, 
vanadate). Another pool, which is reportedly discharged by the alkalinizing agent 
NH4Cl, by the H1 ionophores nigericin and monensin (which operate as K+/H+ and 
Na+/H+exchangers, respectively), by V-type ATPase inhibitors, and by the H1-PPase 
inhibitor aminomethylenediphosphonate has been attributed to an acidic 
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compartment within the parasite. This compartment is postulated to be comprised of 
a population of acidocalcisomes acidic Ca2+ storage organelles which are found in 
trypanosomatids and other apicomplexans  and which are acidified by the combined 
action of a V-type H+-ATPase and a H+-PPase (Kirk, 2001). Another study has 
implicated the parasite’s acidic food vacuole in Ca2+ storage (Biagini et al., 2003). 
However, a recent study questioned conclusions by reporting comparable Ca2+ 
values of 300 and 400 mM for the parasite cytoplasm and food vacuole (Rohrbach et 
al, 2005). P.falciparum merozoites possess electron-dense organelles rich in 
phosphorus and calcium which are similar to the acidocalcisomes of other 
apicomplexans, but of more irregular form. Malaria parasites possess large amounts 
of short and long-chain polyphosphate (polyP), which are associated with 
acidocalcisomes in other organisms. 
Mitochondria of malaria parasites are able to reversibly accumulate part of the 
Ca2+ released in the cytoplasm by pharmacological and physiological agents and 
suggesting that this organelle participates in the maintenance of Ca2+ homeostasis of 
Plasmodia (Gazarini and Garcia, 2004). 
It is still unclear what pathway Ca2+ uses to pass from the blood plasma to the 
parasite, either via the RBC plasma membrane or by a more direct pathway such as 
a duct or the tubulovesicular membrane network (Lauer et al., 1997). 
So far, few genes in Plasmodium spp have been identified and studied that 
are involved in the Ca2+ sensing or in Ca2+ homeostasis. This includes the CDPKs or 
the calcium dependent protein kinases (Li et al., 2000, Christodoulou et al., 2004, 
Moskes et al., 2004), the P-type Ca2+-ATPases (Krishna et al., 2001; Eckstein-
Ludwig et al., 2003; Trottein et al., 1995), and the Ca2+ binding protein (Polson and 
Blackman, 2005). In addition the parasite has a putative Ca2+ /H+.                                                                                                              
 
A Ca2+/proton exchanger activity was first discovered in bacteria (Tsuchiya 
and Rosen, 1976). In E. coli, Ca2+/proton exchanger activity extrudes Ca2+ from the 
cell when coupled to a pH gradient across the membrane (Zimniak and Barnes, 
1980). In yeast, a Ca2+/proton exchanger ScVCX1 localized to the vacuole 
membrane was found to confer tolerance to high external concentrations of Ca2+ 
(Cunningham and Fink, 1994; Cunningham and Fink, 1996). To date Ca2+/proton 
exchangers have been characterized in plant, yeast, and microbial species (Pittman 
and Hirschi, 2001) and in some animal tissues (Villa et al., 1998;Cordeiro et al., 2000, 
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Goncalves et al., 2000). Ca2+/proton exchangers have in general 10–14 
transmembrane (TM)-spanning domains with about 400 amino acid residues 
(Waditee et al., 2004). A Ca2+/proton exchanger in cyanobacteria may be localized to 
the plasma membrane (Waditee et al., 2004). Information on the molecular properties 
of Ca2+/proton exchangers has emerged from studies on plant Ca2+/proton 
exchangers, especially from Arabidopsis spp (Cheng et al., 2003). Four Arabidopsis 
Ca2+/proton exchangers (AtCAX1–4) were identified by their ability to sequester Ca2+ 
into yeast vacuoles in Saccharomyces cerevisiae mutants deleted of the vacuolar 
Ca2+-ATPase and the Ca2+/H+ antiporter (ScVCX1). It was shown that AtCAX1, 
AtCAX3, and AtCAX4 specifically transport Ca2+, whereas AtCAX2 transports Ca2+, 
Mn2+, and Cd2+. Those vacuolar type AtCAXs share an N-terminal autoinhibition 
domain and a conserved 9-amino-acid motif required for Ca2+ transport (Ca2+ domain) 
(Cheng and Hirschi, 2003). 
So far, evidence for a Ca2+/proton exchanger in Plasmodium across the 
parasite plasma membrane are based mainly on the possible coupling of Ca2+ 
transport in intraerythrocytic parasites to a proton-motive force across the Plasmodia 
plasma membrane. The evidence for the cotransport is based on the observations 
that H+-ATPase inhibitor dicyclohexylcarbodiimide (DCCD) and the protonophore 
carbonyl-cyanide-m-chlorophenylhydrazone (CCCP) inhibited 45Ca2+ influx and 
stimulated efflux from infected cell (Tanabe et al., 1982; Tanabe et al., 1983; Kramer 
and Ginsburg, 1991). 
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1.3 Aim of the study 
 
The mortality and morbidity of malaria are increasing, in part because 
parasites acquired  drug resistance mechanisms (Snow et al., 2001). Given the 
limited antimalarial arsenal, the widespread of resistance and the unavailability of a 
vaccine, the short term strategy can only rely on the development of new 
compounds. One approach toward the development of new compounds is the 
identification of new target in the parasite. The parasite´s transporters are now 
seriously considered to be potential drug targets. Some have already been validated 
as drug target (Joet and Krishna, 2004). 
The calcium metabolism has been proven to be vital for eukaryotic cells and 
even a slight variation in Ca2+ levels can be fatal. In P. falciparum, previous studies 
have highlighted the crucial role of calcium in major processes of the parasite life 
such as invasion, exflagellation, or important metabolic reactions. Targeting the 
sarco-endoplasmic reticulum Ca2+-ATPase of P.falciparum by artemisinin, and its 
derivatives has proven to be an antimalarial option. Moreover, CQ resistance is 
reversible by verapamil, a Ca2+ channel blocker. However, the calcium metabolism is 
poorly understood and few genes involved in this metabolism are known. 
With the completion the of genome sequence of P. falciparum, a putative Ca2+ 
proton exchanger has been identified. It is a single copy gene with few homologies to 
human proteins. In order to further understand the calcium homeostasis and to 
evaluate this exchanger as a drug target, the aim of this study was to functionally 
characterize the putative transporter using two heterologuous system: yeast and the 
Xenopus oocyte system. 
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2. MATERIAL AND METHODS 
2.1 Material 
 
2.1.1 Laboratory equipment 
Analytic Scale L310 and 1872  Sartorius, Göttingen  
Autoclave      Tuttnauer Systec 2540, Wettenberg 
Camera (Gel photos)    Kodak, DC120 Zoom Digital Camera 
Centrifuge J2-MC     Beckmann, Krefeld 
Centrifuge Megafuge 2.0R   Heraeus Instruments, Hanau 
Centrifuge RC5BPlus    Sorvall, Langenselbold 
Confocal laser scanning microscope Zeiss, Jena 
LSM 510 
Computer-Software: 
Axo Tape 2.0   Axon Instr., USA 
Adobe Photoshop®5.0  Adobe Systems Inc, USA 
Sigma Plot 9.0   Jandel Scientifics, USA 
EndNote 8.0.0   ISI Research Soft, CA, USA 
MS Word 98    Microsoft Corporation, CA, USA 
Internet Explorer   Netscape Communications Corp., USA 
Developer Hyperprocessor  Amersham Pharmacia Biotech, Freiburg 
Electrophoresis apparatus    Biorad, Munich 
Mini Sub-Cell GT     
Electrophoresis apparatus Model 96 Biorad, Munich 
Electroporator (Parasites)   Biorad, Munich 
 Gene pulser II  
Electroporation (for E. coli transformation) Equibio, Easyject prima 
Film exposition cassettes   Sigma, Taufkirchen 
Fluorescent microscope    Zeiss, Axiovert 100M, Jena 
Freezer      Liebherr, Biberach 
 
Freezer –80°C, UF85-300S   Heraeus GmbH, Hanau 
Fridges     Liebherr, Biberach 
Gas burner gasprofi 1 micro   WLD - TEC 
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Gel dryer model 583   Biorad, Munich 
Gel stainer      Pharmacia 
GS Gene Linker UV Chamber   Biorad, Munich 
Heating Block Laboratory devices  INC, Digi-Block JR, USA 
Hybridisation tubes    Techne, Cambridge, UK 
Hood      The Baker Company 
Hybridisation oven HB-1D   Techne, Cambridge, UK 
Ice machine AF 30     Scotsman, Mailand, Italy 
Incubationer (Bacterial)    Heraeus, Function line 
Incubationer (cell culture)    Heraeus, Cell Star Incubator, cytoperm 2 
Incubator shaker innova 4000  New Brunswick Scientific Co.Inc 
Incubator shaker innova 4300  New Brunswick Scientific Co.Inc. 
Inverse Microscope Olympus IMT-2  Olympus, Hamburg 
Inverse Microscope Axiovert 25   Zeiss, Jena 
Light microscope Leica DMIL   Leica Microsystems, Wetzlar 
Light microscope Axiolab    Zeiss, Jena 
Liquid nitrogen tank BT40   Air Liquide, Ludwigshafen 
Liquid scintillation counter, TRI-CARB 2100 Packard, Billerica, USA 
MACS      Miltenyi Biotee 
Magnetic stirrer MR 3001   Heidolph, Schwabach 
Nanoject automatic injector   Drummond, Broomall, USA 
PCR-Machine T96   gradient            Biometra, Göttingen   
Thermocycler   
pH-Meter      WTW, pH 537 
Pipetman Gilson P20, P200, P1000  Abimed, Langenfeld 
Pipetman Pipetus-akku   Hirschmann Labortechnik, Eberstadt 
Pipette: Multipette® plus   Eppendorf, Hamburg 
Powder free examination gloves  Hartmann 
Power supply Power Pac 300  Biorad, Munich  
Power supply EPS 601   Amersham Pharmacia Biotech, Freiburg 
Printer hp Laserjet 1300    Hewlett Packard, Heidelberg 
Protein blotting apparatus   Biorad, Munich 
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Mini Trans Blot  Protein electrophoresis Biorad, Munich 
equipment Mini-Protean® 3 
Puller P-87      Sutter Instruments, USA 
Pump P-50      Amersham Pharmacia Biotech, Freiburg 
Quartz cuvettes    Hellma, Müllheim 
Rotors  
SS-34, GS-3, GSA, SM24  DuPont Instruments, Bad Homburg 
 JA 14, JA 20    Beckman 
 SW 41Ti    Beckman 
Scintillation counter LS6000IC  Beckman 
Semi-dry transfer cell   Biorad, Trans-blot SD 
Stereomicroscope Stemi 2000   Zeiss, Jena 
Spectrophotometer  UVIKON 923  Kontron Instrument  
Table-top Centrifuge (Biofuge pico)  Heraeus, Hanau 
Timer      Roth, Karlsruhe 
Ultracentrifuge RCM11206X   Sorvall, Langenselbold 
Ultracentrifuge L60    Beckman 
UV-Handlamp Typ N-6 L    Benda Laborgeräte and Ultraviolettstrahler 
Vortex      Heidolph, REAXtop, Vortex Genie 2 
Vortex-Genie 2     Scientific Industries, Roth, Karlsruhe 
Water Bath Julabo 7A   Julabo, Seelbach 
 
2.1.2 Disposables 
 
Aluminium Foil     Roth, Karlsruhe 
Cell culture plates 6, 24, 96 wells  Nunc, Wiesbaden und Greiner bio-one, 
Frickenhausen 
Cover slips      Roth, Karlsruhe 
Cryopreservation tubes   Nalgene 
Electroporation cuvette (5 mm)   Bio Rad, Gene Pulser (for transfection) 
Easyject, EQUIBIO prima (for bacteria) 
Eppendorf tube     Sarstadt 
Film       Kodak, BioMax or X-OMAT 
Glass wool      VWR International 
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Glass capillaries      Helmut Saur, Reutlingen 
Drummond # 3-0000203-G/X 
Gloves      Unigloves GmbH, Troisdorf 
Immersion oil     Zeiss, Jena 
Immuno-Blot™ PVDF Membrane           Biorad, Munich 
MACS-columns CS    Miltenyi Biotec, Bergisch Gladbach 
Membrane for DNA blotting   Machery-Nagel 
Microcentrifuge tubes (0.5 ml, 1,5 ml)  Sarstedt, Nürnbrecht 
Microscope slides     Marienfeld, Lauda-Königshof 
Mineral oil molecular biology tested Sigma 
Nylon membrane (positively charged)  BoehRinger Mannheim 
Nitrocellulose membrane    Sartorius 
Parafilm American International            CanTM, Chicago, USA 
PCR-tubes      Greiner bio-one, Frickenhausen 
Pasteur pipettes    Roth, Karlsruhe 
Petri dishes      Greiner bio-one, Frickenhausen  
Pipette Tipps    Greiner, Nürtingen /Steinbrenner, Heidelberg 
Plastic cuvette     Sarstedt, Nürnbrecht 
Plastic pipettes (1, 2, 5, 10 und 25 ml)   Corning incorporation, Bodenheim 
Plastic falcons (15/50 ml)    Greiner bio-one, Frickenausen 
Plastic wrap saran    Roth, Karlsruhe 
Scintillation vial    Beckman 
Scintillation cocktail    Lumafase 
Sterile filters (0.2 µm, 0,4 µm)   Schleicher & Schuell, Einbeck 
Sterile filter units (500, 1000 ml)   Corning incorporation, Bodenheim 
Thermowell tubes (for PCR)   Corning Incorporation 
WhatmanTM 3MM paper             Whatman Paper Company 
 
2.1.3 Chemicals 
 
All chemicals not listed were bought from the companies Roth, Merck, Sigma, 
Serva, J.T. Baker and AppliChem via the Chemical store of the University of 
Heidelberg, Germany. 
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Acrylamide/Bisacryl 30 %    Serva, Heidelberg 
Agar      Fluka 
Agarose (for electrophoresis)   Invitrogen 
Agarose      Gibco BRL, Karlsruhe 
Ammonium acetate    Ferak 
Ammonium carbonate    Ferak 
Ammonium persulphate    Biorad, Munich 
Ampicillin (Na salts)    Applichem 
Ampicillin      Sigma, Taufkirchen 
Aprotinin      Sigma, Taufkirchen 
Artemisinin     Sigma, Taufkirchen 
Bacto-Agar      Difco Laboratories, Augsburg 
Bacto-Peptone     Difco Laboratories, Augsburg 
ß-Mercaptoethanol     Merck, Darmstadt 
Bradford reagent     Biorad 
Bromophenol Blue (Na salts)   Serva 
BSA      AppliChem 
Calcium chloride    Merck, Darmstadt 
45CaCl2      Perkin Elmer, Boston, USA 
Chloroform      Merck, Darmstadt 
Chloroquine     Sigma, Taufkirchen 
Coomassie Brilliant Blue R 250   Serva 
Coomassie Brillant Blue G 250   Biorad 
DAPI       Sigma, Taufkirchen 
Diethylpyrocarbonate (DEPC)   Sigma, Taufkirchen 
DMSO      Merck, Darmstadt 
dNTP-Kit     Peqlab, Erlangen 
DTT       Sigma, Taufkirchen 
EDTA      Roth, Karlsruhe 
Ethidium bromide     Sigma,Taufkirchen 
Formaldehyde     Merck, Darmstadt 
Gentamycin      Gibco BRL, Karlsruhe 
Giemsa      Sigma, Taufkirchen 
D(+)-Glucose     Merck, Darmstadt 
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Glycerol (Glycerin)     Gerbu, Gaiberg 
Glycine      AppliChem 
HEPES (free acid)     Roth, Karlsruhe 
Hydrochloric acid     Baker 
Hypoxanthine     CCPro 
Isopropanol      Baker 
Lanthanum chloride    Sigma, Taufkirchen 
Leucine     Serva, Heidelberg 
Leupeptin     Sigma, Taufkirchen 
Lysine     Serva, Heidelberg 
Magnesium chloride    J. T. Baker 
Magnesium sulphate    Sigma, Taufkirchen 
MOPS      Sigma, Taufkirchen 
Paraformaldehyde     Serva, Heidelberg 
PBS       Biochem 
PMSF      Sigma, Taufkirchen 
Potassium acetate     AppliChem 
Potassium carbonate    Ferak 
Potassium chloride     Roth, Karlsruhe 
Pre-stained protein marker  Peqlab, Erlangen 
Quinine     Sigma, Taufkirchen 
RPMI 1640-Medium    GibcoBRL, Karlsruhe  
SDS       AppliChem 
Sephadex G-50    Amersham 
Skim milk power     Fluka 
Sodium chloride     Merck, Darmstadt 
Sodium hydrogen phosphate   Sigma, Taufkirchen 
Sodium hydroxide     Merck, Darmstadt 
Sucrose      Serva, Heidelberg 
TEMED      Sigma, Taufkirchen 
Tris-Base      Roth, Karlsruhe 
Triton X-100      Sigma, Taufkirchen 
Trypton/peptone     Roth, Karlsruhe 
Tryptophane     Serva, Heidelberg 
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Tween20      Merck, Darmstadt  
Uracil      Sigma, Taufkirchen 
Verapamil      Sigma, Taufkirchen 
Xylene cyanol FF     Sigma, Taufkirchen 
Yeast extract     Difco Laboratories, Augsburg, Germany 
 
2.1.4 Antibodies 
 
Anti-GFP     Roche Diagnostics, Mannheim 
Anti vacuolar alkaline phosphatase Molecular probes 
Anti-HA     Dianova, Hamburg 
Anti-mouse POD    Jackson ImmunoResearch Laboratories 
Anti-Rabbit POD     BöhRinger, Mannheim 
 
2.1.5 Enzymes 
 
Calf intestinal phosphatase  Roche Diagnostics, Mannheim 
Collagenase A (Typ II; 2 mg/ml)   Roche Diagnostics, Mannheim 
DNA-Polymerase Pfu   Promega, Mannheim    
DNase I      Stratagene, Heidelberg 
Klenow polymerase    New England BioLabs, Schwalbach 
E. coli DNA polymerase I   USB 
Proteinase K     Roche Diagnostics, Mannheim 
Protein kinase    New England BioLabs, Schwalbach 
Restriction enzymes    New England BioLabs, Schwalbach 
                Amersham Pharmacia, Freiburg 
RNase A      Roche Diagnostics, Mannheim 
Shrimp alkaline phosphatase  Promega, Mannheim 
Taq DNA-Polymerase    Biotaq RED Bioline, Luckenwalde 
T4-DNA-Ligase     New England BioLabs, Schwalbach 
Zymolase 20T    ICN 
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2.1.6 Nucleic acids 
 
Synthetic oligonucleotides as well as primers have been synthesized by the 
firm Invitrogen in Karlsruhe (Germany). The sequencing of DNA was made by 
Geneart. 
 
2.1.6.1 Oligonucleotides  
 
pSP64T forward  AGAATACAAGCTTGCTTGTTC 
pSP64T reverse GTAAGTTGGGTATTATGTAGC 
Ca 5´ BglII GCGCCGAGATCTAAAATGGTTATGGGTAGAG 
Ca 3´BglII AGAGATCTCATTAGGAGG 
Ca 3´BglIIstop AGAGATCTTTTACATTAGGAGG 
Ca 5´ Hind III ACCAAGCTTAAAAATGG 
Ca 3´ BamHI GCGGGGATCCGGAGGTATCGAACC 
Ca3´BamHIstop GCGGGGATCCTTAGGAGGTATCGAACC 
Ca600 5´ CCAACTTGTTGTTGGTTTG 
Ca 950 3´ AATTCGGAATGAATGGAAACC 
Ca3´BglIIHA AATTAAAGATCTTTAAGCATAATCTGGAACATCATATGGATAGGAGGT 
ATAGAACCAGAAAAC 
Vcx-5´ Hind III GCTCAAGCTTACAATGGATTGCAACTACC 
Vcx-3´ BamHI CGCGGATCCTAAACTATTTCCAATAG 
Vcx-3´ BamHIstop CGCGGATCCTCATAAACTATTTCCAATAG 
VcxPstI-3´ AATATACTGGAGATCATACACAGCTG 
CaPstI-5´ ATGCCTGCAGAACATGTTGAACTC 
5 UTR 5´ GGGTCTGCTTCAGTAAGCC 
3 UTR 3´ TCTAGAGTCGACCTGCAGG 
ADHpro CTGCACAATATTTCAAGC 
ADHter GCAAGGTAGACAAGC 
GFP-100 ACCGTAAGTAGCATCACC 
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2.1.6.2 Plasmids  
 
pSP64T (S. Krishna, London) 
pVT100-U (J. Stolz, Regensburg) 
pVT GFP (J. Stolz, Regensburg) 
pGEM-T (Promega, Mannheim) 
 
2.1.6.3 Electrophorese markers 
RNA-marker     New England Biolabs, Schwalbach 
1 kb DNA-marker     New England Biolabs, Schwalbach 
Roti® Mark Prestained    Roth, Karlsruhe 
Prestained Marker, broad range   GibcoBRL, Karlsruhe 
 
 
2.2 Methods 
 
2.2.1 Parasitology 
 
2.2.1.1 In vitro culture of Plasmodium falciparum 
3D7 strain parasites were cultured by an adaptation of the method of Trager 
and Jensen (Trager and Jensen, 1976). The erythrocytic forms of P. falciparum were 
cultured in Petri dishes of 10 cm or 25 cm diameter. In a 10 cm diameter dish were 
mixed 14 ml of the parasite medium, 0.5 ml of fresh A+ erythrocytes concentrate and 
some drops from a previous parasite culture. Respectively were mixed 30 ml of 
medium and 1.5 ml of fresh erythrocytes as well as some drops of infected 
erythrocytes for the 25 cm diameter Petri dish, so that the hematocrit was 
approximately 5%. The parasitaemia was checked and the medium changed every 
two or three days. In case the parasitaemia was higher than 5-10%, the culture was 
diluted in a new plate to avoid a death of parasites due to high levels of degraded 
products in the medium. The parasite cultures were incubated in an atmosphere of 3 
% CO2, 5 % O2, 92 % N2, and 95% humidity. 
 
 
 
Material and Methods 
 
 27 
Preparation of the human serum and erythrocytes 
Human group A+ erythrocytes concentrate and A+ human serum was obtained 
from the blood bank of the German Red Cross, Heidelberg. The human serum was 
prepared by the following. It was aliquoted into 50 ml falcon tubes. In each falcon 
tube was added 800 µl of sterile 1 M CaCl2, incubated at 37°C for 30 min and 
overnight at 4°C.  The next day the tubes were centri fuged (4000 rpm, 30 min) to 
pellet the fibrin and incubated at 56°C for 30 min t o inactivate the serum. Thereafter 
the serum was kept at -20°C. The erythrocytes concentrate  was aliquoted into 50 ml 
falcon tubes. 10 ml RPMI medium was added and the tubes were centrifuged (2300 
rpm, 4 min) and then kept for two to three weeks in the fridge. 
 
2.2.1.2. Staining of P.falciparum with Giemsa  
To enable determination of parasitaemia, and parasite stage, thin smears of 
the culture were made as follows: 50 µl of culture was spread evenly onto the surface 
of a clean microscope slide, air dried, fixed in 100% methanol for 30 s, and air dried. 
Fixed cells were stained for 5-10 min in a solution of 10% Giemsa, washed with water 
and allowed to dry. Slides were examined microscopically on a light microscope 
using a 100X objective to view cells under oil immersion. 
 
2.2.1.3 Determining parasitaemia  
The parasitaemia is the percentage of P. falciparum infected erythrocytes. A 
single layer of stained cells was used. The number of both parasites and erythrocytes 
in ten consecutive fields were counted. The parasitaemia was then calculated 
according to the following formula: 
(Number of parasites/Number of erythrocytes) X 100 = parasitaemia in % 
 
2.2.1.4 Freezing parasites 
Only the parasites from the ring stage can be recovered after freezing. The 
parasitaemia should be higher as 5%, to guarantee that the parasites will come up 
quickly after thawing. Infected erythrocytes were pelleted at 1900 rpm for 2 min. The 
supernatant was then removed, and the sediment re-suspended in 1 volume of sterile 
freezing solution (28% Glycerol, 3% Sorbitol, and 0.65% NaCl). The suspension was 
gently mixed, filled into a cryotube and snap frozen in an ethanol/dry ice slurry for 15 
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min. The tube was then transferred to –80oC for not less than one day, before being 
stored at –196oC in liquid nitrogen. 
 
2.2.1.5 Thawing parasites 
The cryotube was removed from the liquid nitrogen tank and thawed in a 37oC 
water bath for 2 min before being transferred to a 50 ml centrifuge tube. Per 1 ml of 
blood was then added 200 µl of 12% NaCl at a rate of 2 drops per second, with 
constant mixing. After a 5 min incubation period at RT, a further 5 ml of 1.6% NaCl 
was then added as before. After further 5 min incubation, 5 ml of 0.9% NaCl/0.2% 
Glucose was then added. The suspension was then centrifuged as before, the 
supernatant removed, the parasite pellet washed in 25 ml of complete parasite 
medium, resuspended in 12 ml of complete parasite medium and transferred to a 
Petri dish. 0.5 ml of fresh blood was then added, and the dish transferred to the 
parasite incubator. The dish was allowed to incubate for 48 h before being treated as 
normal. All solutions were pre-warmed to 37oC before starting the thawing procedure.  
 
2.2.1.6 Parasites synchronisation with sorbitol 
This sorbitol treatment causes osmotic lysis of late stage trophozoites 
(Lambros and Vanderberg, 1979). This selective lysis by osmotic shock is possible 
due to the presence of an induced transport pathway in the red cell membrane that is 
permeable to sorbitol, and absent in ring stage parasites. Culture media was 
removed from the culture dish, and the blood resuspended in 9 volumes of sterile, 
pre-warmed 5% D-sorbitol solution and transferred to a centrifuge tube. After a 5 min 
incubation at room temperature the suspension was then centrifuged (1900 rpm, 2 
min, RT), the resulting pellet being resuspended in complete culture medium and 
returned to the culture dish (Lambros and Vanderberg, 1979). In order to achieve 
either highly or totally synchronised parasite cultures, this procedure was then 
repeated after respectively 48 or 4-6 h. 
 
2.2.1.7 Enrichment of mature stage parasites by magnetic separation 
Malaria parasites metabolise the haemoglobin of the erythrocyte, producing 
non-soluble oxidised haem products, which are then crystallized to give haemozoin 
(Pagola et al., 2000). Due to magnetic properties of haemozoin pigment, it is possible 
to separate trophozoites and schizonts from non-infected and young stage parasites 
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(Uhlemann, 2000). Using this method, it is possible to reach a parasitaemia of 95-
99%. A magnetic column (MACS Separation Columns CS) was secured in the 
magnet holder, following the manufacturers (Vario MACS, Miltenyi Biotec) 
instructions. The column was equilibrated with MACS buffer. A parasite culture was 
then slowly allowed to filter through the column, to allow late stage parasites to bind. 
The column was then washed with approximately 5-6 column volumes of MACS 
buffer, or until the flow-through was clear and contained no further erythrocytes. The 
column was then removed from the magnet and the parasites eluted with 15 ml of 
MACS buffer. The eluted parasites were then pelleted by centrifugation (1900 rpm, 2 
min, RT) and resuspended in the required buffer. 
2.2.1.8 PCR based mycoplasma testing 
While bacterial and fungal infections of cultures are relatively easy to detect, to 
prevent and to treat, contamination with mycoplasmas represents a much bigger 
problem leading to diminished cell growth and eventually to the loss of cultures. 
Mycoplasmas are small free-living, self-replicating organisms between 0.2-2 µm in 
diameter, thus can pass through the sterile filter.  
To test cell cultures for mycoplasma contamination, the following protocol was carried 
out at regular intervals: 
100 µl of medium from parasite cultures were removed heated at 95oC for 5 min and 
then centrifuged at full speed in a microcentrifuge for 5 s. A PCR reaction was then 
set up as follows: 2 µl of each prepared sample are then used for the PCR reaction, a 
positive control being used for every set of reactions. The PCR was performed 
according to the manufacturer’s instructions. After cycling, 5 µl of the reaction mixture 
was analysed on a 1.5% agarose gel. A 500 bp band corresponds to a positive 
mycoplasma contamination. 
 
2.2.2 Cell biology 
 
2.2.2.1 Immunofluorescence assay 
The immune fluorescent assay (IFA) is a method to analyse both expression 
and localisation of specific protein within fixed or pre-treated cells. After cells have 
been fixed, they are subject to treatment with specific antibodies. In the indirect IFA, 
a secondary antibody coupled to a fluorophore is then used to bind the primary 
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antibody. When excited at the correct wavelength, the fluorophore emit visible light, 
allowing visualisation of the fluorescent immune complexes, and thus target protein 
location. The protocol used was as follows: A small aliquot of infected erythrocytes 
(50 µl) was washed X2 in PBS to remove serum and media. The infected 
erythrocytes were then resuspended to 50% haematocrit in PBS. 5 µl of this 
suspension was then placed onto a clean microscope slide, and smeared as usual. 
The film was allowed to dry, and was then fixed for 5 min in acetone/10% methanol at 
-80oC. After fixing, the slides were allowed to dry, and then wells were drawn directly 
onto the slide, using a liquid blocker pen. The prepared slides were blocked overnight 
with 5% skim milk/PBS in a humidity chamber at 4oC. The next morning, the 1o 
antibody was added, diluted in 5% skim milk/PBS and allowed to bind for 2-4 h. The 
slides were washed X3 in PBS/0.01% Tween for 5 min, and then for 5 min in PBS. 
The second antibody was added as above, and after the necessary incubation time, 
the slide was washed as before, allowed to dry and a cover slip added including anti-
fade mounting medium. The slides were viewed on a Carl Zeiss LSM510 confocal 
laser scanning microscope.  
 
2.2.2.2 Confocal microscopy  
Whilst the idea for confocal microscopy has been around for over forty years, 
the first commercially available microscope was introduced in 1987. As opposed to 
conventional microscopy, in which the whole object field is illuminated, confocal 
microscopy illuminates only a small portion of the sample at one time, using a 
focussed laser beam which moves rapidly across the sample. This light is focussed 
through a lens, passes a dichromatic mirror, across several moveable mirrors, 
through the objective and is focused onto the sample. In this way fluorochromes can 
be excited which then emit longer wave light which is then collected by the objective, 
passes back through the dichromatic mirror and is then separated by filters. Normally 
when an object is imaged in a fluorescence microscope, the signal produced is from 
the full thickness of the specimen which does not allow most of it to be in focus to the 
observer. The confocal microscope eliminates this out-of-focus information from 
above and below the plane of focus of the object by means of a confocal "pinhole" 
situated in front of the image plane which acts as a spatial filter and allows only the 
in-focus portion of the light to be imaged.  The scattered light from neighbouring and 
out-of focus areas is thus reduced. Thus, only one point is being viewed at a time. 
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The resulting signal is collected by a photomultiplier-detector (PMT). To build a full 
picture, the sample is rapidly scanned, and the resulting points are then 
reconstructed by the computer to give the finished picture. 
 
2.2.2.3 Sub cellular fractionation of yeast organelles 
The protocol for the subcellular fractionation of yeast organelles was done as 
the following: Cells were grown in 2 L of growth medium at 30°C to the logarithmic 
phase (2.5 OD600 U/ml). Then all steps were performed at 4°C. 
Cells were harvested by centrifugation at 3000 rpm for 8 min. The supernatant was 
discarded and the pellet washed in an equal volume of a 20 mM NaN3 chilled 
solution. The volume of the pellet was estimated by resuspending it in a small known 
volume of the NaN3 solution and the cells were harvested as before. The cells were 
converted to spheroplasts by incubation in 1:1 volume with freshly 20 mg added of 
zymolase, the cell wall lytic enzyme, in a buffer with the following composition: 1.4 M 
sorbitol, 50 mM KPi, 10 mM NaN3, 40 mM ß-ME freshly added. The cells were 
incubated at 30°C in 50 ml falcon tube by gently shakin g. The extent of spheroplast 
formation was determined spectrophotometrically. Every 5 min a 100 µl aliquot was 
removed and diluted in 900 µl of water and the OD600 value determined. As 
spheroplasts lyse in water due to lack of a cell wall, the reduction in the OD600 value 
is directly proportional to the amount of spheroplasts formed. The spheroplasts 
suspension was then centrifuged at 2500 rpm for 10 min. The spheroplasts were 
broken by suspending in a solution of 12% sucrose, 10 mM TEA, 1 mM PMSF, 1 mM 
EDTA. Spheroplasts further breakage was carried out by several up and down 
pipettings through a 22G needle.  The lysate was centrifuged at 2500 rpm for 10 min. 
The supernatant was further centrifuged at 10 krpm for 10 min. The pellet was 
resuspended in a 1 mM MgCl2 solution. The resuspended pellet was placed on top of 
a preformed 25%-55% discontinuous sucrose gradient in Beckman SW41 centrifuge 
tube. The sucrose solution contained 1 mM MgCl2, 1 mM PMSF. The gradient was 
centrifuged at 4°C for 90 min, at 25 krpm in a L8-80 Beckman centrifuge. Ten 3 ml 
fractions were collected from the top of the gradient. The samples were diluted with 2 
vol. of cold water. After centrifugation at 50 krpm, the pellets were resuspended in the 
loading buffer for proteins. 
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Fig. 2.1: Subcellular fractionation of yeast organelles 
 
 
2.2.3 Molecular biology 
 
2.2.3.1 DNA synthesis 
Because of the high AT composition of the Plasmodium genome, the putative 
calcium hydrogen antiporter (pfcha) has been redesigned and synthesized by the firm 
Geneart (Regensburg) to allow an efficient transcription of mRNA in oocytes. The 
yeast codon usage system was used to design the new sequence of DNA to be 
sequenced while keeping the same amino acid sequence as the original putative 
protein sequence.  
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2.2.3.2 Culture and transformation of bacteria 
 
2.2.3.2.1 Bacterial strains 
PMC103 (Doherty et al., 1993): mcrA ∆mcrBC-hsdRMS-mrr102 recD sbcC. 
One Shot® TOP10 Chemically Competent E. coli (Invitrogen): F- mcrA .(mrr-hsdRMS-
mcrBC) Φ80lacZ.M15.lacX74 recA1 deoR araD139.(araleu)7697 galU galK rpsL 
(StrR) endA1 nupG. 
 
2.2.3.2.2 Preparation of competent E. coli 
 
a) Production of chemically competent E. coli 
Chemically competent E. coli  Top 10 cells for standard cloning reactions were 
prepared by a modification of the of the method of Inoue (Inoue et al., 1990). Briefly, 
Top 10 cells were streaked out onto an LB agar plate containing 30 µg/ml of 
streptomycin, and single colonies were allowed to grow overnight. 1 colony was then 
picked and inoculated into 5 ml of LB medium with streptomycin overnight. The next 
morning, 2 ml from the preculture were inoculated into 50 ml of LB medium with 
streptomycin. The cells were allowed to grow at 37°C w ith shaking (250rpm) until an 
OD600 of 0.6 had been reached. The cells were harvested in a 50 ml falcon by 
centrifugation at 4000 rpm for 10 min at 4oC. The pellet was washed in ice cold 0.1 M 
CaCl2, centrifuged once more as above and the pellet was resuspended in 2 ml of ice 
cold 0.1 M CaCl2. 200 µl of glycerol was added, mixed, and the cells were aliquoted 
to 50 µl in microcentrifuge tubes and frozen in a dry ice/ethanol bath for 15 min. Cells 
were transferred to –80oC for storage. The competence of the cells was checked by 
transformation. The cells were competent when the transformation efficiency was at 
least 106 cfu per µg of plasmid. 
 
b) Production of electro-competent E. coli  
Ultra-competent PMC103 E. coli were prepared as follows: A single colony 
was picked from a freshly prepared LB agar plate and inoculated into 10 ml of Super 
Broth. This culture was shaken (250 rpm) overnight at 37oC. The following morning, 
this culture was diluted 1:100 in a further 600 ml of Super Broth and allowed to shake 
further for 3.5 h at 37oC. Cells were harvested at 7000 rpm for 10 min at 4oC. The 
resulting pellet was washed a total of three times in 600 ml of ice cold Millipore water 
Material and Methods 
 
 34 
with centrifugation as above. One further wash was carried out with 600 ml of ice cold 
10% glycerol and the cells were then re-suspended in 1.2 ml of 10% glycerol before 
being snap frozen in 100 µl aliquots in an EtOH/dry ice slurry. Cells were transferred 
to –80oC for storage 
 
2.2.3.2.3 Transformation of competent E. coli  
 
a) Transformation of chemically competent E. coli 
An aliquot of cells was removed from –80oC and allowed to thaw on ice. The 
cells were incubated on ice for 10 min with repeated gentle mixing (Cosloy and Oishi, 
1973). The DNA was added,   gently mixed and the mixture was incubated on ice for 
a further 30 min. Cells were then heat shocked in a 42oC water bath for 30 seconds, 
and immediately returned to ice for 2 min before addition of pre-warmed at 37°C 150 
µl of SOC medium. The tube was then transferred to a 37oC shaker for 1hr to allow 
recovery. Transformation reactions were then spread onto LB agar plates containing 
the appropriate selective antibiotic and transferred to a 37oC incubator overnight.  
 
b) Transformation of electro-competent E. coli 
The cells were allowed to thaw on ice and then divided into 50 µl aliquots. The 
DNA was added and the mixture was then transferred to a pre-chilled 0.2 cm gap 
cuvette. Electroporation took place at 2.5 kV. in a gene pulser II (Biorad). The cuvette 
was then returned to ice and a disposable Pasteur pipette was used to add 1 ml of 
pre-warmed SOC media, and transfer the transformation mix to a 15 ml tube. From 
this point on the protocol progresses as that for chemically competent cells. 
 
2.2.3.2.4 Production of glycerol stocks 
The required colony was inoculated into super broth containing the required 
selective agent, and incubated overnight. The culture was then mixed 1:1 with a 
sterile solution of 20% glycerol, aliquoted into cryotubes and stored at –80oC for up to 
two years. 
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2.2.3.3 Culture and transformation of yeast 
 
2.2.3.3.1 Yeast strain 
S. cerevisiae strain K667 (MATa ade2-1 can1-100 his3-11, 15 leu2-3, and 112 trp1-1 
ura3-1 cnb1::LEU2 pmc1::TRP1 vcx1  ) 
 
2.2.3.3.2 Transformation of yeast 
The protocol followed the small scale yeast transformation protocol from 
Invitrogen. 10 ml of YPD medium was inoculated with one colony and shaked 
overnight at 30°C. The next morning the culture was diluted to an OD600 of 0.4 in 50 
ml of YPD medium and grew for an additional 4 h. The cells were then pelleted at 
2500 rpm for 10 min and resuspended in 40 ml of 1X TE. The cells were pelleted one 
more time as before and resuspended in 2 ml of 1X LiAc/0.5X TE and incubated at 
room temperature for 10 min. For each transformation, 1 µg of plasmid DNA, 100 µg 
denatured sheared salmon sperm DNA and 100 µl of the yeast culture were mixed 
together. 700 µl of 1X LiAc/40% PEG-3350/1X TE was added, well mixed and 
incubated at 30°C for 30 min. Then was added 88 µl of  DMSO and the cells were 
heat shocked for 7 min at 42°C. The cells were pelleted , washed in 1X TE and re-
pelleted and resuspended in 50-100 µl 1X TE and plated on a selective plate. The 
plate was incubated for at least 3 days at 30°C. 
 
2.2.3.3.3 Production of glycerol stocks 
The selected yeast colony was inoculated into YPD medium and incubated 
overnight. The culture was then mixed 1:1 with a sterile solution of 20% glycerol, 
aliquoted into cryotubes and stored at –80oC for up to two years. 
 
2.2.3.4 Isolation and purification of DNA  
 
2.2.3.4.1 Isolation of plasmid DNA from E. coli 
 
a) Minipreparations for restriction digest 
To obtain plasmid DNA for restriction endonuclease digestion, a miniprep 
method following the protocol from Sambrook (Sambrook, 1989) was used. Briefly a 
single colony was grown overnight in 10 ml of LB medium containing the appropriate 
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by incubating in a shaker. The next morning the culture transferred to a 14 ml tube 
was pelleted by centrifugation (4000 rpm, 10 min, 4°C ). The pellet was resuspended 
in 500 µl of solution A, lysed on ice with 1 ml of solution B for 3.5 min. 750 µl of 
chilled solution C was added to precipitate the proteins and the genomic DNA. The 
mix was centrifuged (10 krpm, 10 min, 4°C). 2 ml of th e supernatant was taken and 
added to 5 ml of ethanol, vortexed and centrifuged as above. The pellet was 
resuspended was in 0.5 ml of solution D and 1 ml of ethanol was added, then vortex 
and centrifuged again as before. The pellets was dried and after resuspended with 
200 µl of TE and transferred to a microcentrifuge. The suspension was centrifuged 
(13 krpm, 5 min) and the supernatant containing the plasmid DNA was transferred to 
a new microcentrifuge. 1 µl of 10 mg/ml RNAse A. was added. 
 
b) Minipreparation for sequencing  
To ensure that sequencing reactions achieved good results, and maximum 
read length, a commercial mini-preparation kit was used to obtain highly pure plasmid 
DNA (High Pure Miniprep, Roche, Mannheim). Following the manufacturers’ 
recommendations yielded 10 µg of high quality plasmid DNA 
 
c) Midiprep and Maxiprep 
To obtain higher amounts of DNA, the Qiagen Plasmid Maxi Kit was used. The 
plasmid purification protocols are based on a modified alkaline lysis procedure, 
followed by binding of plasmid DNA to QIAGEN Anion-Exchange Resin under 
appropriate low salt- and pH conditions. Plasmid DNA is eluted in a high-salt buffer 
and then concentrated and desalted by isopropanol precipitation. The DNA yield was 
respectively for the midiprep and the maxiprep 100 µg and 500 µg. 
 
2.2.3.4.2 Determination of DNA concentration and purity 
Determination of DNA concentration was carried out using a UV-
spectrophotometer to measure absorption of DNA solutions at OD260 and OD280. The 
OD260 was used to calculate the dsDNA concentration using the following formula: 
(OD260 x dilution factor x 50)/1000= DNA concentration (µg/ml). As the absorption 
wavelengths of protein overlaps that of DNA and can therefore cause the DNA 
concentration to be overestimated is necessary to measure OD280, allowing a 
measure of DNA purity to be calculated using the following formula: 
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OD260/OD280 = relative purity of DNA. A figure of between 1.8-1.9 is a sign of 
extremely pure DNA. At a ratio 260/280 of 1, only 50% of the OD260 reading is 
actually DNA, the rest being protein (Sambrook, 1989). 
 
2.2.3.4.3 Precipitation of DNA (Ream, 1999) 
To precipitate DNA, 2 vol of 100% ethanol at -20oC and 0.1 vol of 3M NaOAC (pH 
5.2) were added to the DNA solution in a microcentrifuge tube. After mixing the tube 
was kept at -20°C for at least 30 min and then was spun at full speed in a 
microcentrifuge for 15 min at 4oC. The supernatant was removed, and the DNA pellet 
washed with 70% ethanol, centrifuged as before. The supernatant was removed and 
the pellet allowed to dry, and resuspended in a suitable buffer.  
 
2.2.3.4.4 DNA analysis by agarose gel electrophoresis (Darbre, 1999) 
Agarose gel electrophoresis was used  to estimate double stranded DNA 
concentration, to size fractionate fragments for restriction enzyme mapping , to 
isolate specific DNA fragments for cloning and to visualise the result of PCR 
amplification. Typically, 0.8-1.5% agarose gels (w/v in 1xTAE buffer, containing 0.5 
µg/ml ethidium bromide) were cast and submerged in 1xTAE buffer. DNA samples 
were mixed with 6xDNA loading buffer (5:1), loaded into the wells and separated at a 
constant voltage of between 5-10 V/cm. DNA was visualised by UV (312 nm) 
transillumination and sized by comparison with 1kb+ DNA marker. When necessary, 
DNA bands were visualised using a hand held long wave UV lamp to avoid damage  
to the DNA, excised from agarose gels using a clean cover slip and purified using the 
Qiagen gel extraction kit, following the manufacturers´ protocol.  
 
2.2.3.4.5 Purification of DNA  
DNA was purified (for example after enzymatic manipulations, PCR products) 
either according to the method of Sambrook, or using a modified protocol from the 
Qiagen PCR purification kit. 
 
a) Phenol/chloroform extraction  
The solution volume was adjusted to 500 µl with water. An equal volume of 
TE-saturated phenol/chloroform/isoamyl alcohol (25:24:1) was added and mixed by 
vortexing. The phases were separated by centrifugation in a microcentrifuge for 10 
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min at full speed. The upper aqueous layer was then removed to a fresh tube. 
Depending upon the purity of the initial DNA, this step may have been repeated. To 
remove carried over phenol; one volume of chloroform was added and mixed by 
vortexing. The sample was then centrifuged again as above and the aqueous layer 
containing purified DNA removed to a fresh tube.   
 
b) Purification using a Qiaquick column 
The principle of Qiaquick system is based on the selective binding properties 
of a uniquely-designed silica-gel membrane. DNA adsorbs to the silica membrane in 
the presence of high salt while the contaminants pass through the column. The pure 
DNA is then eluted with Tris-buffer or water. For DNA samples in solution 5 volumes 
of buffer PB (Qiagen) were added to the sample. The sample was then loaded onto 
Qiaquick column and spun at maximum speed in a microcentrifuge for 1 min. The 
Flow through was discarded and the column was washed with 750 µl of buffer PE. 
The column was dried by centrifugation as above and the sample eluted into a fresh 
tube with 30-50 µl of EB (Qiagen). The same kit was used for the purification of DNA 
from agarose gels but with some modifications. The cut agarose gel was solubilised 
by adding the buffer QG and incubating for 10 min at 50°C. The sample was loaded 
onto the Qiaquick column and the protocol was followed as describe above for the 
DNA sample in solution. 
 
2.2.3.5 Enzymatic manipulation of DNA 
 
2.2.3.5.1 Restriction endonuclease digestion of DNA 
Plasmid DNA for restriction analysis was digested for 1-2 h at the 
manufacturers recommended temperature, and in the recommended 1X reaction 
buffer. Typically, 1 µg of plasmid DNA was digested with 1 unit (U) of enzyme in an 
end volume of 20 µl. Double digests were carried out either in a buffer compatible 
with both enzymes, or in a sequential manner. Preparative restriction digests (for 
cloning) were carried out for 4 h as above, to ensure complete digestion of original 
plasmid DNA. The total volume of these reactions was also increased to 50 µl to 
ensure complete cleavage.  
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2.2.3.5.2 Enzymatic DNA amplification by polymerase chain reaction (PCR) 
DNA was amplified by PCR. For analytical PCR reactions, the Taq DNA-
Polymerase (MBI Fermentas and Bioline) were used. DNA fragments for cloning 
purposes were amplified using proofreading polymerases: The Phusion® polymerase 
(Finnzymes) and the mixture of Pfu (Promega, Mannheim) and Taq polymerase. 
The PCR was done according to the manufacturers´ protocols.  
 
2.2.3.5.3 DNA ligation  
T4 DNA ligase catalyses the formation of a phosphodiester bond between 
juxtaposed 5´phosphate and 3´hydroxyl termini in duplex DNA or RNA. This enzyme 
will join blunt end and cohesive end as well. Ligation reactions were carried out in a 
20 µl volume at 16oC overnight or 1h at room temperature. Fragments for ligation 
were run on an agarose minigel to allow a rough estimation of relative concentration. 
A typical reaction contained at least 100 ng of DNA at a plasmid:insert molar ratio of 
1:3. Before transformation of electrocompetent E. coli cells, the ligation reaction was 
ethanol precipitated to remove salts and re-suspended in 10 µl of water. 5 µl was 
then used to transform E. coli.  
 
2.2.3.5.4 Dephosphorylation of sticky ends 
To avoid re-ligation, de-phosphorylation of plasmid DNA sticky ends was 
carried out using shrimp alkaline phosphatase (SAP) or the calf intestinal 
phosphatase (CIP). Alkaline phosphatase catalyses the removal of 5´ phosphate 
group from DNA, RNA. Since alkaline phosphatase treated fragments lack 
5´phosphoryl termini group required by ligases, they cannot self-ligate. De-
phosphorylation of sticky ends was done according to the manufacturers´ protocols. 
 
2.2.3.5.5 “Fill in” or blunt end reaction with Klenow fragment  
Prior to ligation of none-cohesive DNA fragments, 5´ overhangs were filled in and 3´ 
overhangs were removed to form blunt ends by the polymerase Klenow. The reaction 
was done as the following: 10 µl DNA, 2.5 µl 10x Klenow buffer, 1 µl each dNTP, 2 µl 
Klenow (5U/µl), dH2O to 25 µl. Reaction was allowed to proceed for 1 h at 30oC, and 
then phenol/chloroform extracted and concentrated by EtOH precipitation. If needed, 
products were digested with the appropriate restriction enzymes, purified and ligated 
(total amount) to target vector.  
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2.2.3.6 Methods on RNA 
 
2.2.3.6.1 Isolation of RNA from Plasmodium falciparum 
RNA was isolated from parasites using a modification of the method of Kyes et 
al (Kyes et al., 2000). It is important during RNA isolation to ensure that possible 
contamination with RNAses is reduced to a minimum. For this reason, it is desirable 
to use disposable, RNAse free plastic labware, and to try to limit the amount of time 
that the RNA is in contact with the atmosphere, as many RNAses are found freely 
floating in the air. All reactions were be carried out on ice, unless stated otherwise. 
Gloves were changed at regular intervals. 12 ml of culture at >5% parasitaemia, 
containing mainly trophozoite and schizont parasites stages was pelleted by 
centrifugation (1900 rpm, 2 min, 4oC). The pellet was resuspended in PBS containing 
0.01% saponin. The tube was placed on ice for 10 min to ensure complete lysis, 
before being subjected to a second centrifugation step (1900 rpm, 10 min, 4oC). The 
parasite pellet was resuspended in 5 ml of Trizol (Gibco). 1 ml of chloroform was 
added and the contents of the tube were mixed well by vortexing. The sample was 
centrifuged at (10000 g 10 min, 4oC). The upper aqueous phase was removed to a 
fresh tube and the RNA precipitated by addition of 0.8 vol of isopropanol. The tube 
was left at –20oC for at least 1 h before centrifugation at 10000 g for 1 h to pellet the 
precipitated RNA. The resulting pellet was allowed to dry under sterile conditions, 
and resuspended in 200 µl of DEPC treated sterile DIW, containing 1 µl of RNAse 
OUT RNAse inhibitor.  
 
2.2.3.6.2 cRNA synthesis  
The cRNA for injection in oocytes was made using the kit from Ambion 
mMESSAGE mMACHINE, a kit for the in vitro synthesis of large amount of capped 
RNA. Capped RNA mimics most eukaryotic mRNAs found in vivo, because it has a 
7-methyl guanosine cap structure at the 5´ end during polymerisation, which strongly 
increases RNA stability.  
The cRNA was made following the manufacturer’s protocol. Briefly, the 
template used for the reaction was prepared as following: 10 µg of the plasmid 
containing the SP6 promoter was linearized with an enzyme cutting downstream the 
cDNA after the poly A (+) site. The restriction digest was purified with the QIAGEN 
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PCR purification kit and ethanol precipitated as mentioned in 2.2.3.4.5 and 
resuspended to a final concentration of 1 µg/µl.  
1 µg of the linearized template was added to the transcription reaction mixture 
to a final volume of 20 µl and incubated for 2 h. At the end of the incubation, the DNA 
was degraded by DNase I treatment for 15 min. The RNA was recovered by the 
lithium chloride precipitation: The reaction was stopped and RNA precipitated by 
adding 30 µl of nuclease free water and of the LiCl solution, chilled for 30 min at -
20°C pelleted by centrifugation at maximum speed at 4 °C. The pellet was washed 
with 70% ethanol and repelleted. The pellet was resuspended in nuclease free water 
to a concentration of 1 µg/µl and stored at -80°C.      
 The transcription products were analysed by a 0.7% agarose gel 
electrophoresis containing ethidium bromide under denaturing conditions with 
formaldehyde. The samples diluted 1 to 1 with the 2X loading buffer were heated for 
3-5 min at 85°C and then loaded on the gel. After r unning the gel, the products were 
visualized on the gel using a UV transilluminator. Pfcha coding sequence was 
subcloned into the BglII site of the pSP64T oocyte expression vector that 
encompasses the 5´ and 3´ untranslated regions of the X. laevis ß-globin gene 
(Falcone and Andrews, 1991). The pSP64Tcha plasmid was linearized with BamHI, 
and capped cRNA was synthesized by the mMessage mMachineTM (Ambion, Inc., 
Austin, TX). Oocytes were microinjected with 25–50 ng of cRNA. 
 
2.2.3.7 Protein analysis and detection 
 
2.2.3.7.1 Determination of protein concentration (Bradford method) 
Upon binding protein, the absorption spectrum of Coomassie brilliant blue G-
250 shifts from 465 nm to 595 nm. The increase in absorption by 595 nm is a 
measure of the protein concentration of the solution (Bradford, 1976). Using 
calibration curves of known protein concentration, it was possible to calculate the 
protein concentration of P. falciparum and E. coli extracts prior to SDS-PAGE.  
 
2.2.3.7.2 Preparation of P.falciparum protein extracts 
Sequential extraction of parasite material was carried out as follows: 1.5 ml of 
PRBC at parasitaemia of >5% were pelleted by centrifugation (1900 rpm, 2 min RT). 
The resulting pellet was resuspended in 10 ml of sterile DIW to osmotically lyse 
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erythrocytes and the lysate then centrifuged as above. The parasite pellet was 
washed x3 in PBS to remove residual haemoglobin. The parasite pellet was 
resuspended in 250 µl of buffer A (See appendix) transferred to a microcentrifuge, 
and incubated on ice for one hour, with periodic vortexing. The tube was centrifuged 
for 10 min (13000 rpm, 4oC), and the supernatant, containing the Triton-X-100 
soluble fraction removed to a separate tube and mixed with 250 µl of 2X SDS loading 
buffer. The remaining pellet was then resuspended in 125 µl PBS, before addition of 
125 µl 2X SDS loading buffer. Both fractions were then boiled in a heat block for 4 
min. Insoluble material in the SDS soluble fraction was removed by centrifugation 
(13000 rpm, 10 min, 4oC). Both fractions were frozen at –80°C until needed .  
 
2.2.3.7.3 Preparation of membrane proteins extracts from Xenopus  
To get membrane proteins for western blot, 20 oocytes were injected with 
cRNA and incubated for 3 days at 18°C for expression of the PfCHA protein. The 
oocytes were then placed in a microcentrifuge tube. From this step, everything was 
done on ice to avoid any protease activity. 400 µl (20 µl per oocyte) of the 
homogenizing buffer were added to the oocytes and they were broken using a 
special homogenizer. The mixture was spun for 10 min at 4°C at 3 krpm in a 
microcentrifuge. Three phases were obtained: the upper phase contained yolk 
proteins, the lower phase the debris, and the middle phase the membrane proteins 
which were carefully pipetted and transferred to another tube and centrifuged for 1 h 
at 4°C at 50 krpm. The supernatant was mixed with the pellet from the first 
centrifugation and the pellet containing the membrane proteins was resuspended in 
20 µl (1 µl/oocyte) of homogenizing solution. 
 
2.2.3.7.4 SDS-Polyacrylamide gel electrophoresis 
Polyacrylamide-Gel electrophoresis (PAGE) was used to separate proteins 
from bacterial and parasite cell lysates, for use in either Coomassie staining, or 
protein blotting experiments. Prepared protein samples were stored at –20oC until 
needed. Uniform gel concentrations were prepared in a Protean II or Mini Protean 
vertical electrophoresis apparatus (Biorad). Glass plates were cleaned in methanol, 
rinsed in water and dried prior to assembly of the casting apparatus. A separating 
gel, typically 10% was cast and overlaid with water to achieve a flat interface; 
polymerisation was allowed to take place. The water was then removed by aspiration 
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and stacking gel cast above the separating gel, containing an appropriately sized 
comb. After polymerisation, the gel holder was removed from the casting holder and 
transferred to the electrophoresis tank. The tank was filled with 1x SDS running 
buffer. The comb was then removed, and the wells were "rinsed" using a syringe, to 
ensure that no unpolymerised acrylamide remained in the bottom of the wells. 
Samples and a suitable pre-stained molecular weight marker were loaded. 
Electrophoresis was carried out at constant current (15 mA per gel) until the samples 
exited the stacking gel, at which point the current was increased to 30 mA per gel. 
Electrophoresis was stopped when the bromophenol blue front reached the end of 
the gel. Plates were dismantled and the gels either stained with Coomassie blue to 
visualise proteins, or processed further for western blotting. 
 
2.2.3.7.5 Western analysis 
Western blotting was performed in a Mini Protean chamber (Biorad). The 
sponge was wetted with 1x transfer buffer and placed on the black side of the blot 
sandwich apparatus. Two pieces of 3MM paper were cut to size, and wetted with 1x 
transfer buffer and placed on top of the sponges. The resolved gel was then carefully 
placed on top of the 3MM paper. A suitably sized piece of PVDF membrane was 
activated in 100% methanol and equilibrated for 10 min in 1x transfer buffer before 
being carefully placed on top of the gel, ensuring that no air bubbles were present 
between gel and membrane. Two further pieces of 3MM paper and the final sponge 
were wetted in 1x transfer buffer, and placed on top of the assembled stack. The 
sandwich apparatus was closed and transferred to the blotting chamber, ensuring 
that the black side of the sandwich apparatus corresponded to the black side of the 
sandwich holder. The transfer tank was filled with 1x transfer buffer; a small stirrer 
bar was placed in the bottom of the tank. The entire apparatus was then placed in a 
plastic bath full of crushed ice and moved to a stirrer in a cold-room. Transfer took 
place at 100 V constant for 1 h. After transfer, the membrane was removed from the 
blotting apparatus, and blocked in PBS/milk powder for at least one hour. The 
membrane was then incubated for between 1-2 h at RT with primary antibody, diluted 
to a suitable concentration in PBS/5% skim milk powder. The membrane was then 
washed for 3x20 min in PBS/tween-20 at RT. Incubation with secondary antibody 
was carried out as for the primary, for 30 min-1 h at RT. The membrane was then 
washed for 3x20 min in PBS/0.1% Tween-20 at RT. Detection was performed using 
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the ECL detection system as recommended by the manufacturer. The exposure of 
autoradiographic films was performed in a dark room using a film cassette to insure a 
tight fit between membrane and film. Usually, 1 s up to 30 min exposure was 
performed. 
 For horseradish peroxidase based secondary antibodies, the membrane was 
immersed for several seconds in developing solution, allowed to drip dry, placed 
between a folded piece of transparency film attached to a suitably sized sheet of 
3MM paper and placed in the film cassette. After exposure for a suitable period of 
time, the film was developed.  
 
2.2.4 Functional assays 
 
2.2.4.1 Oocytes expression  
The female frogs were obtained from CNRS, Montpellier, France, or from 
Xenopus Express, Vernassal, France. Stage V-VI oocytes were harvested from X. 
laevis and defolliculated with collagenase (Sigma). For oocyte extraction, the frog 
was first anaesthetized by 15 min incubation in an ice-cold solution containing 2 mM 
Ethyl-n-aminobenzoat-methansulfonate. The frog was then brought on ice and a 
small incision was made to remove the oocytes. After isolation of the frog’s oocytes, 
the incision was closed immediately and the frog was washed with water and 
returned to the tank. The oocytes were separated with fine forceps. The follicular cell 
layer was removed from the oocytes by 45 min incubation in a calcium free solution 
(OR2 solution) containing 2 mg/ml collagenase. After incubation, oocytes were 
washed first with OR2 solution and then with OR2 solutions containing increasing 
concentrations of calcium and finally with the SOS solution in which the oocytes are 
kept. Oocytes were allowed to recover from the collagenase treatment for at least 2 h 
before injection of RNA. Oocytes were injected at the latest the day after the 
collagenase treatment. The oocytes from stages V-VI were selected for cRNA 
injection. Pipettes used for cRNA injection were pulled using a standard pipette 
puller. Pipettes with an opening of ~15-20 µm in diameter were polished to obtain a 
needle-like shape which reduces oocytes damage during injection. Microinjection of 
cRNA (~50 nl per oocyte) was performed using an automatic injector. 
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2.2.4.2 45Ca2+ uptake experiments 
Standard uptake solutions was made of Ringer solution containing 10 µCi/ml 
of 45Ca2+, buffered with  5 mM Hepes, tricine or MES, respectively for the pHs 7.5, 
8.5 and 6.5.  In each batch of experiment, ten oocytes from both negative control 
(water injected oocytes) and  cRNA  injected oocytes were separately placed for 
different periods of time into 500 µl of the same solution supplemented with 10 µCi/ml 
45Ca2+. Uptake was performed at room temperature. For uptake experiments in 
presence of inhibitors, oocytes were preincubated for 15 min in a solution containing 
the inhibitor and then incubated in radioactive solution containing the inhibitor for 1 h. 
At the end of the incubation period oocytes were thoroughly washed three times with 
large volumes of the ice-cold Ringer solution with the corresponding pH in order to 
remove the extracellular radioactivity. Each individual oocyte was subsequently 
placed into a separate scintillation vial, dissolved for 30 min with 200 ml of 5% SDS, 
before addition of 2.5 ml of scintillation fluid, and the solution was counted for 
radioactivity in a Beckman LS2100 scintillation counter. 
 
2.2.4.3 Extracellular pH measurements 
A qualitative assay of external medium acidification was designed to estimate 
H+ secretion by the oocytes. The assay followed a protocol from Jaissier et al. 
(Jaisser et al., 1993). 3 days after injection of cRNA, the oocytes were transferred in 
a weakly buffered solution (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1mM MgCl2, 500 
µM MOPS adjusted to pH 8.1 with NaOH), containing the pH indicator Red phenol 
(200 mg/l). Oocytes were placed individually in a small drop of the same solution 
under oil. The volume of the droplet was then reduced to 0.5 to 1.0 µl by gently 
removing the solution with a thin glass pipette. After 1h incubation at room 
temperature, a picture was taken. 
 
2.2.4.4 Membrane potential and internal pH measurements 
The membrane potential and the internal pH were simultaneously measured 
with double barrelled microelectrodes. They were constructed as described 
previously (Anagnostopoulos and Planelles 1987, Cougnon et al. 1996). The pH 
sensitive channel was backfilled with the H
+
-Ionophore 95291 from Fluka and the 
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shaft filled with 67 mM NaCl, 40 mM KH
2
PO
4 
und 23 mM NaOH. The Na
+
 selective 
electrode was backfilled with Fluka 71196 and the shaft filled with 100 mM NaCl.  
 
2.2.4.5 Growth assays 
The PfCHA gene was expressed in S. cerevisiae defect in calcium tolerance 
strain. One single yeast transformed colony was picked and inoculated in 10 ml of 
selective medium. The incubation was done at 30°C in a shaker (300 rpm) for 2 days 
to reach the stationary phase. 10 µl of this preculture were then inoculated into 10 ml 
of fresh selective medium and further incubated under the same conditions. In case 
different plasmid constructs were grown in parallel under the same conditions to be 
compared, the starting optical densities were checked and adjusted to be identical. At 
various time points, aliquots of the cultures were removed and growth was 
determined by measuring the optical density at 600 nm. Alternatively, in other 
experiments, the preculture was diluted to an OD600 of 0.4 and further grown to an 
OD600 of 1.0. Serial dilutions were made and 10 µl from each dilution was spotted 
onto selective agar plates and the plates were incubated at 30°C at least for 3 days. 
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2.3 Appendix: Solutions, Buffers, media and miscellaneous    
 
2.3.1 Solutions 
 
Homogenizing solution for oocytes 
Sucrose        
Sodium phosphate pH 7.4    
Aprotinin              
Leupeptin               
PMSF       
0.3 M 
10 mM 
40 µg/ml 
20 µg/ml 
1 mM 
 
Ampicillin (sodium salt) 
Stock concentration   
Working concentration             
100 mg/ml 
100 µg/ml 
 
Streptomycin 
Stock concentration   
Working concentration             
50 mg/ml 
30 µg/ml 
 
Solutions for yeast transformation 
 
10X LiAc   
Lithium Acetate pH 7.5                   1 M 
Adjust the pH to 7.5 with dilute glacial acetic acid and bring up the volume to 
100 ml. Sterilize with a filter and store at room temperature. 
 
1X LiAc/0.5X TE  
Lithium Acetate pH 7.5 
Tris-HCl pH 7.5 
EDTA   
100 mM 
      5 mM 
   0.5 mM 
Sterilize with a filter and store at room temperature. 
 
 
 
Material and Methods 
 
 48 
50% PEG-3350 
For 100 ml, dissolve 50 g of PEG-3350 in 90 ml of deionised water. You may 
have to heat the solution to fully dissolve the PEG. Bring up the volume to 100 ml 
with deionised water. Autoclave and store at room temperature. 
 
1X LiAc/40% PEG-3350/1X TE 
Lithium Acetate pH 7.5 
PEG-3350  
Tris-HCl pH 7.5 
EDTA   
100 mM 
       40% 
   10 mM 
1 mM 
Prepare solution immediately prior to use. For 100 ml, mix together 10 ml of 
10X LiAC, 10 ml of 10X TE, and 80 ml of 50% PEG-3350. Sterilize with a filter. 
 
Solutions for oocytes experiments 
 
OR-2 solution 
NaCl  
KCl 
MgCl2 
Hepes 
    100 mM 
2  mM  
1 mM 
5  mM 
  pH 7.6 with NaOH. Add 800 µl of 50 mg/ml gentamycin in 400 ml of solution. 
 
SOS solution 
NaCl  
KCl 
CaCl2  
MgCl2 
Hepes 
    100 mM 
2  mM  
     1.8 mM 
1 mM 
5  mM 
  pH 7.6 with NaOH. Add 800 µl of 50 mg/ml gentamycin and 500 µl of 220 
mg/ml pyruvate in 400 ml of solution. 
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Ringer solution 
NaCl  
KCl 
CaCl2  
MgCl2 
Hepes 
      96 mM 
2  mM  
        1 mM 
1 mM 
5  mM 
 pH 7.5 with NaOH. Use 5 mM MES or tricine to pH Ringer solution at pH 6.5 or 
8.5. 
 
2.3.2 Buffers 
 
50X Tris-acetate-EDTA (TAE) 
Tris base 
Glacial acetic acid 
0.5 M EDTA pH 8.0 
242 g 
     57.1 ml 
      100 ml 
 
5X Tris-borate-EDTA (TBE) 
Tris base 
Boric acid 
0.5 M EDTA pH 8.0   
       54 g 
    27.5 g 
20 ml 
 
Buffers and gels for electrophoresis of RNA 
 
20x MOPS-Buffer                                                 
MOPS   
Natriumacetate 
EDTA pH 8.0 
H2O dest.  
     0.4 M 
   40 mM 
     5 mM 
ad 500 ml 
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RNA gel 
MOPS-Buffer 
LE Agarose  
Formaldehyde 
1x 
      0.7% 
2.2 M 
 
Buffers  and  gels for SDS-PAGE 
 
Stacking gel        
H2O 
Acrylamide (29:1)   
1 M Tris-HCl pH 6.8        
10% APS 
TEMED                             
       3.4 ml 
830 µl 
630 µl 
         50 µl 
           5 µl  
                                             
Separating gel 12% 
H2O   
Acrylamide (29:1) 
1,5 M Tris-HCl pH 8.8 
10 % SDS 
10% APS 
TEMED  
   3.3 ml 
4.0 ml 
     2,5 ml 
     100 µl 
     100 µl
  6 µl 
 
Running buffer 1x    
Glycin 
Tris/HCl, pH 6.8 
SDS  
    250 mM 
      25 mM 
      0.1% 
 
2 x SDS protein sample buffer 
Tris-HCl pH 6.8 
Mercaptoethanol 
SDS  
Bromophenol blue 
Glycerol 
100 mM 
         2% 
         4% 
         2% 
       20% 
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Transfer buffer 1x         
Tris-base   
Glycin     
SDS  
   48 mM  
39 mM 
13 mM          
 
TBS 1x 
Tris-HCl pH 7.5 
NaCl  
   50 mM 
   0.15 M 
   
TBST 1x 
TBS  
Tween 20 
1x 
      0.1% 
 
  
2.3.2 Media  
 
The parasite medium  
RPMI 1640 with 25 mM HEPES, L-Glutamin, NaHCO3 
10% human serum (A+) 
Hypoxanthin                10 mM 
Gentamycin                         4 µg/ml 
 
Media for bacteria 
 
LB medium 
Tryptone 
Yeast extract 
NaCl  
1% 
0.5% 
      0.5% 
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Super Broth 
Tryptone 
Yeast extract 
NaCl 
NaOH   
3.5% 
2% 
      0.5% 
  5 mM 
 
LB agar plates 
LB medium 
Agar                      1% 
For agar plates, after autoclaving of the LB agar, it was let cooled down to 
50°C, antibiotic was added and the agar was poured on Petri dishes. 
 
SOC medium 
Bacto-Trypton 
Yeast extract 
NaCl 
KCl  
MgCl2  
MgSO4 pH 6.8-7.0 
        2 %                           
0.5 % 
10 mM 
        5 mM 
     10 mM 
10 mM 
     Before addition of magnesium salts, media were sterilised by autoclavation. 
Mg2+ salts were prepared separately, sterile filtered and added to the autoclaved 
medium. 
 
Media for yeast 
 
YPD  
Yeast extract 
Peptone 
Glucose 
         1% 
2% 
         2%  
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YPD selective medium Ca2+ 
 Yeast extract 
Peptone  
Glucose 
Ca2+   
         1% 
         2% 
2% 
200 mM 
pH 5.5 with NaOH 
 
YPD selective medium Mn2+ 
Yeast extract 
Peptone 
Glucose 
Mn2+  
         1% 
         2% 
         2% 
         10 mM 
 
YNB medium 
Yeast nitrogen base   
Casamino acids      
Glucose          
Tryptophan 
0.67%               
0.5% 
         2% 
       0.01% 
  
Solutions of glucose, tryptophan and Ca2+ were separetely filter sterilized and added 
to the medium after autoclavation. 
 
YPD agar: YPD, 2% agar 
YPD selective medium Ca2+ agar: YPD selective medium Ca2+, 2% agar     
YNB agar: YNB, 2% agar 
 
2.3.4 Miscellaneous 
 
MACS buffer 
PBS   
BSA% 
EDTA  
           1x 
       0.5% 
       2 mM 
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RNA Transcription reaction: 
Nuclease free H2O  
10x reaction buffer    
2x NTP     
Template  
Enzyme                   
ad 20 µl  
2 µl 
10 µl 
1 µg 
       2 µl 
 
6X gel loading buffer (10 ml) 
Glycerol 
EDTA 0.5M 
Bromophenol blue 
Xylene cyanol 
DIW  
6 ml 
1.2 ml 
9 mg 
9 mg 
      2.8 ml 
 
1 kb+ marker (600 µl) 
1kb+ DNA ladder (Gibco) 
6X loading buffer 
1XTAE buffer 
50 µl               
100 µl 
        450µl 
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3. RESULTS 
 
The calcium/hydrogen antiporters are known to be involved in various 
metabolic and physiological pathways in eukaryotic cells (Saris and Carafoli, 2005). 
In Plasmodium previous studies have postulated the existence of a calcium/hydrogen 
antiporter involved in important mechanisms in the parasite (Tanabe et al., 1982; 
Tanabe et al., 1983; Kramer and Ginsburg, 1991). The completion of the genome 
sequence of P. falciparum in 2002 has provided the information about a putative 
calcium hydrogen antiporter. To confirm and study the role of this putative gene in 
calcium homeostasis in P. falciparum, it was cloned and expressed in yeast and 
Xenopus laevis oocytes for characterization.   
Because of the high A/T content of the Plasmodium genome, which has 
already been shown to be problematic for expression in heterologuous system (Baca 
and Hol, 2000), the sequence was redesigned and synthesized on the basis of the 
yeast codon usage. The gene was subsequently cloned in the oocyte expression 
vector pSP64T and the yeast expression vectors pVT100 and pVT100-GFP2.  
 
3.1 Sequence features 
Pfcha is a gene encoding  a polypeptide of 441 amino acids, exhibiting 46% 
sequence identity (60% similarity) to the yeast vacuolar Ca2+/H+ antiporter VCX1. It 
was also found to be 40% identical (53% similar) to the mung bean vacuolar Ca2+/H+ 
antiporter VCAX1 and 37% identical (52% similar) to the Arabidopsis thaliana 
vacuolar Ca2+/H+ antiporter. 
Like others transporters from the calcium exchanger gene family, PfCHA 
contains a central hydrophilic motif that is rich in acidic amino acids, and which 
bisects the polypeptide into two groups of five and six transmembrane domains (Fig. 
3.1). Computer-assisted hydropathy analyses of PfCHA generated a profile with an 
equivalent spacing and alternation of hydrophilic with hydrophobic domains, 
consistent with intrinsic membrane proteins that span the membrane 11 times (Fig. 
3.2). It contains an N-terminus hydrophilic region that is similar to the CAX1 
autoinhibitory domain. It contains also several phosphorylation sites and an acidic 
rich motif not found in the CAX-like gene family.  
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        1                                                   50 
AtCAX1  ~~MAGIVTEP WSVAENGNPS ITAKGSSREL RLGRTAHNMS SSSLRKKSDL  
 PfCHA  MVMGRVRATS YVRRTISQP. ..LNKNVPPM KNMKNVNGLK DTNLIRNRNL  
VCAX-1  ~~MGSHQHEP WLLE.NGNP. ...KVLTREM RHGRTAHSKS SNSLRTKSDR  
 VCX-1  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~MDA TTPLLTVANS  
        51                                                _100 
AtCAX1  RVIQKVP... ....YKGLKD FLSNLQEVI. .......... .....LGTKL  
 PfCHA  HLQLLCNNKM PAGMYDDELT KVYDLEETLP FYYPRKSDIY GMQNMLNSKL  
VCAX-1  TLVSKVP... ....CATIRN VLFNLQEVI. .......... .....LGTKL  
 VCX-1  HPARNPK... ....HTAWRA AVYDLQYIL. .......... .....KASPL  
               
        101___M1___________    _________M2___________      150 
AtCAX1  AILFPAIPAA IICTYCGVSQ PWIFGLSLLG LTPLAERVSF LTEQLAFYTG  
 PfCHA  NVLLIFVPIG LLSHFFGFKD IYIFFFNFMV LIPLSALMGH VTEDLALHTG  
VCAX-1  SILIPAIPVA IVAEYCGFGR PWVFVLSLLG LTPLAERVSF ITEQVAFYTG  
 VCX-1  NFLLVFVPLG LIWGHFQLSH TLTFLFNFLA IIPLAAILAN ATEELADKAG  
        151_________M3______________          ___M4_______200 
AtCAX1  PTLGGLLNAT CGNATELIIA ILALTNNKVA VVKYSLLGSI LSNLLLVLGT  
 PfCHA  EIIGGLLNAT FGNLMEMIFS IQALNAGLIN VVQGTLLGSI LSNLLLVLGM  
VCAX-1  PTVGGLLNAT CGNVTELIIA IFALSSNKIA VVKYSLLGSI LSNLLLVLGT  
 VCX-1  NTIGGLLNAT FGNAVELIVS IIALKKGQVR IVQASMLGSL LSNLLLVLGL  
        201_____                _________M5 _______________250 
AtCAX1  SLFCGGIANI RREQRFDRKQ ADVNFFLLLL GFLCHLLPLL VGYLKNGEAS  
 PfCHA  SFFAGGLYHH ..IQKFNEKG ATCSTSLLLL SSLAITIPTV SSFT......  
VCAX-1  SLLCGGIANV GLEQKYDRRQ GDVNSLMLLL ALLCYLLPML FKYS...AAS  
 VCX-1  CFIFGGYNRV ..QQTFNQTA AQTMSSLLAI ACASLLIPAA FRATLPHGKE  
        251             ____________M6___________          300 
AtCAX1  AAVLSDMQLS ISRGFSIVML ISYIAYLVFQ LWTHRQLFDA QEQ.EDEYDD  
 PfCHA  TNNNLDVILK VSRITAVLIF VTYCLFLLFQ LYTHISLFQD KE........  
VCAX-1  AALTVDPSLH LSRASSIVML IAYVVYIIFQ LWTHRQLFEA ED..EDEDDN  
 VCX-1  DHFIDGKILE LSRGTSIVIL IVYVLFLYFQ LGSHHALFEQ QEEETDEVMS  
                                                     
        301        __________M7_________                   350 
AtCAX1  DVE.QETAVI SFWSGFAWLV GMTLVIALLS EYVVATIEEA SDKWNLSVSF  
 PfCHA  .MT.EEIPQL SVISGSIFLI LITLLVSIHS EFLIYSIDSV IKYYNISENF  
VCAX-1  NGS.DEQAVI GLWSGIAWLI GMTVFIALLS EYVVDTIEDA SDSWGLSVSF  
 VCX-1  TISRNPHHSL SVKSSLVILL GTTVIISFCA DFLVGTIDNV VESTGLSKTF  
         
        351________M8___________            _______M9______400 
AtCAX1  ISIILLPIVG NAAEHAGAVI FAFKNKLDIS LGVALGSATQ IGLFVVPLTI  
 PfCHA  IGVILLPVVG NATEHLTAVT VAMKNKVDLT MGVAVGSSAQ IALFVVPVTV  
VCAX-1  LSIILLPIVG NAAEHAGAVI FAFKNKLDIS LGVALGSATQ IAMFVVPLCV  
 VCX-1  IGLIVIPIVG NAAEHVTSVL VAMKDKMDLA LGVAIGSSLQ VALFVTPFMV  
        401___     _____________M10_________     _____M11__450 
AtCAX1  IVAWILGINM DLNFGPLETG CLAVSIIITA FTLQDGSSHY MKGLVLLLCY  
 PfCHA  LFGWILNKPM TLAFSPLSTV ILVISVIVTM AIVQDGESNW LEGVLLISAY  
VCAX-1  IVAWTMGVKM DLNFNILETG SVALAIIVTS FTLQDGTSHY MKGLVLLLCY  
 VCX-1  LVGWMIDVPM TLNFSTFETA TLFIAVFLSN YLILDGESNW LEGVMSLAMY  
        451______                               490 
AtCAX1  FIIAICFFVD KLPQKQNAIH LGHQAMNNVV TATGGGVFSS  
 PfCHA  LIVGVVFWFD TS~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~  
VCAX-1  IVIGACFFVQ RTP..FNQAD VTNVIPNGVL SA~~~~~~~~  
 VCX-1  ILIAMAFFYY PDE..KTLDS IGNSL~~~~~ ~~~~~~~~~~  
 
 
Fig. 3.1: Alignment of deduced amino acid sequences of polypeptides encoded by A. 
thaliana CAX1, the putative PfCHA, the mung bean VCAX1 and the S. cerevisiae 
VCX1. Sequences were aligned using CLUSTAL. Gaps were introduced to maximize 
the alignments and are denoted by hyphens. The 11 putative transmembrane domains 
(M1-M11) predicted for all transporters and the in acidic residues in the central 
hydrophilic are shown in italics. 
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Fig. 3.2: Hydropathy plot of PfCHA. Phosphorylation sites (letters in open circle) were determined 
using the Netphos programme. Transmembrane domains are indicated in the boxes. Acidic amino 
acid motifs (grey coloured circles) are shown.  
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3.2 Functional complementation of pfcha in yeast 
 
Several  Ca2+/H+ exchangers have been characterized in yeast (Hirschi et al., 
1996, Pozos et al., 1996). To evaluate the Ca2+-transport activity of PfCHA, it was 
introduced into S. cerevisiae K667 deleted for vacuolar Ca2+/H+ antiporter (VCX1), 
the vacuolar Ca2+-ATPase (PMC1) and the manganese resistance protein (CNB1). 
This strain is unable to grow on high Ca2+ media. In the present experiment, PfCHA 
was inserted between the aldehyde dehydrogenase promoter (ADH) and terminator 
of the pVT100U vector. pVT100U has uracil as a selectable marker. For the GFP-
tagged variant of PfCHA, it was inserted in a pVTGFP vector. This vector has the 
same features as pVT100U and a GFP-tag at the 3´end upstream of the ADH 
terminator. GFP was at the C-terminus of PfCHA (Fig. 3.3).   
As PfCHA may not contain the signal sequences to direct it to the yeast 
vacuole, a chimera construct was made by fusing the N-terminal part and the first 
transmembrane domain of vcx-1 to the pfcha gene minus its first transmembrane 
domain (Fig. 3.3). As a control we investigated VCX1, the yeast vacuolar Ca2+/H+ 
antiporter. 
 
 
Fig. 3.3: Constructs for expression in yeast. Vector alone (A). The PCR amplified 
HindIII/BamHI fragment of pfcha was cloned between ADH promoter (ADHp) and 
terminator (B), between ADHp and GFP (C), as well as the fragments HindIII/PstI of vcx1 
and PstI/BamHI of pfcha (D) 
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We first investigated the subcellular localisation of PfCHA in transformed yeast 
cells. In order to determine the subcellular localisation of the expressed proteins from 
our different constructs, several of experiments were performed. Initially, a 
fluorescence microscopy localization of GFP-tagged PfCHA, VCX1 and VCXPfCHA 
was performed. Yeast containing plasmids with the tagged-proteins were grown in 
selective media untill the logarithmic phase and observed under the confocal 
microscope using a 488nm laser. Confocal imagings of GFP fluorescence emitted 
from the transformed cells suggested a vacuolar localization of PfCHA (Fig. 3.4a). 
Although it is difficult to distinguish the ER from the vacuole in those pictures, the 
localisation of the green fluorescence in the positive control, VCX-1GFP and 
PfCHAGFP are similar. The chimera protein VCXPfCHA has also similar localization 
(data not shown). Given the previous evidence of the VCX-1 localisation to the 
vacuole and the similar fluorescence pattern, the data favour a localisation of PfCHA 
to the vacuole in yeast.  
To further confirm this evidence, a biochemical subcellular localisation 
experiment was performed. The yeast expressing PfCHAGFP were grown to the 
stationary phase and lysed. The organelles were separated by sequential 
centrifugations and a sucrose gradient centrifugation. Proteins from different fractions 
of the sucrose gradient were separated on SDS-PAGE gels, and then transferred to 
nitrocellulose membranes. The membranes were probed with an anti-GFP antibody 
and an anti-vacuolar phosphatase antibody. The GFP antibody recognized a 80 kD 
protein which is consistent with the sum of sGFP (28 kD) and PfCHA (48 kD). The 
result of the Western analysis showed that the GFP-tagged protein containing 
fractions correlated with vacuolar phosphatase (Fig. 3.4b). This data further supports 
the evidence that PfCHA is localised to the vacuole in yeast.  
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Fig. 3.4a: Subcellular localisation of GFP-tagged proteins by confocal microscopy. Cells were visualized by 
fluorescence microscopy during the logarithmic growth. Rows represent different digital zooms from the same 
magnification. In each panel: top left, GFP fluorescence; top right, differential interference contrast (DIC); 
bottom right, merge. 
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Fig. 3.4b: Subcellular localisation of GFP-tagged PfCHA. The ∆pmc1 ∆vcx1 ∆cnb1 yeast 
strain was transformed with the construct pVTGFPpfcha and grown in selective medium. 
Cells were harvested by centrifugation and converted to spheroplasts by zymolase 
treatment. Spheroplasts were lysed by resuspending in a solution of 12% sucrose, 10 mM 
TEA, 1 mM PMSF, 1 mM EDTA. Cell debris was pelleted and the supernatant containing 
the organelles was loaded on the top of a sucrose gradient (25-55%). After centrifugation, 
10 fractions were collected. Proteins extracts from each fraction were separated by SDS-
polyacrylamide gel electrophoresis and transferred to nitrocellulose. Proteins were 
immunodetected with antibodies for GFP and the vacuolar alkaline phosphatase α-ALP. 
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Being localized to the vacuole, we wanted to test if pfcha has 
calcium/hydrogen antiporter activity in yeast. For this purpose, a calcium tolerance 
assay was performed. The calcium tolerance assay investigates the yeast´s 
resistance to high Ca2+ concentration (200 mM) in moderately acidic conditions (pH 
5.5) on agar plates (Hirschi et al., 1996). In this calcium tolerance assay, pfcha as 
well as the chimera vcxpfcha were not able to complement the phenotype. As shown 
in Fig. 3.5, both constructs could not grow on yeast plates supplemented with 200 
mM Ca2+ at pH 5.5. Even after one week incubation, the growth between PfCHA and 
the negative control (the triple mutant) were comparable. In contrast, VCX1 grew 
normally. Surprisingly the chimeric protein VCXPfCHA did not grow as well. The 
antiport activity function has probably been abrogated by the fusion. 
Because there was no growth on agar plates, the calcium tolerance assays 
were repeated in liquid medium supplemented with 200 mM Ca2+ at pH 5.5, under 
vigorous shaking at 30°C. The growth of yeast was determ ined by measuring the 
OD600 of the medium at various time points. Under these conditions, pfcha was able 
to complement the calcium deficient to a certain extent. Indeed, the OD600 at day was 
7 for PfCHA in comparison with VCX1 which was 17. The growth of PfCHA was 
significantly higher than the negative control (Fig. 3.6a).  
 
Salt stress has previously been shown to stimulate calcium transport activities 
in yeast (Cheng et al., 2002). Other reports have established that a P-type Ca2+ 
ATPase are induced by salt stress in plant (Perez-Prat, 1992,Wimmers, 1992). It is 
speculated that salt stress causes increases in cytosolic Ca2+ concentration. To 
investigate if the salt stress could stimulate the growth, PfCHA containing yeast cells 
were grown in the same selective liquid medium as described above and 
supplemented with various concentrations of NaCl. Growth was determined by 
measuring the OD600. According to the results summarized in Fig. 3.6c, NaCl seems 
to have no influence at the used concentrations in the growth of PfCHA yeast. 
  
Some calcium hydrogen antiporters are actually called cation hydrogen 
transporters due to their capacity to transport diverse divalent cations (Shigaki et al., 
2003). BLAST analysis has shown high similarities of pfcha with the yeast 
manganese resistance protein. To test if PfCHA could transport Mn2+, a manganese 
tolerance experiment was performed. Yeast cells were grown in YPD medium 
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supplemented with 10mM Mn2+ and the growth was measured spectrophotometrically 
at day 4 (OD600). There was almost no growth (OD600 was less than 1.0 at day 4) for 
all the constructs (Fig. 3.6d). That VCX1 containing cells did not grow is expectable 
as it does not transport Mn2+. Although we did not have a positive control, it is likely 
that the absence of growth is due to the incapability of PfCHA to transport Mn2+. 
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Fig. 3.5: Calcium tolerance assay. Overnight yeast cultures were diluted to OD600 0.4 
and further grown in a shaker at 30°C to OD 600 of 1.0 in YNB medium. The negative 
control (double mutant) was grown under the same conditions in YPD medium. Cells 
were diluted 4-fold and 10µl of each dilution was spotted on YNB plates without uracil (-
URA) (A) and 10µl on YPD plates pH 5.5 supplemented with 200 mM CaCl2 (B). Plates 
were incubated for 3 days at 30°C 
OD600      1               0.3          0.1        0.03       0.01 
PfCHAVCX 
PfCHA 
VCX1 
Mutant  
PfCHA 
VCX1 
Mutant 
  PfCHAVCX 
OD600     1               0.3           0.1        0.03       0.01 
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Fig. 3.6:  Yeast complementation assays 
(A) Yeast calcium tolerance assay in selective medium. Yeast cells were preincubated in YNB 
medium without uracil for 2 days. Then 10 µl was incubated in 10 ml of selective medium (pH 5.5, 
200mM Ca2+). OD600 was measured every day. Filled circle, vcx-1; open circle, vector alone; filled 
triangle, negative control; open triangle, pfcha, filled square, vcxcha. (B) Growth of yeast in normal 
YPD medium. Open circle, double mutant; filled circle, vcxcha; filled triangle, pfcha. (C) Yeast 
growth in selective medium with various concentrations of NaCl. Yeast was preincubated in YNB 
medium without uracil for 2 days. Then 10 µl was incubated in 10 ml of selective medium (pH 5.5, 
200 mM Ca2+) containing 0mM NaCl (black bars), 200 mM NaCl (light grey bars), and 400 mM (dark 
grey bars). OD600 was measured at day 4. (D) Yeast Mn2+ tolerance assay. The different yeast cells 
was preincubated in YNB medium without uracil for 2 days. 10µl was incubated in 10 ml of selective 
medium made of YPD supplemented with 10mM Mn2+. The OD600 was measured at day 4. 
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3.3 Functional expression of putative pfcha in Xenopus oocytes 
 
The Xenopus expression system is a valuable tool for studies of 
heterologuous pumps, channels and transporters (Weber, 1999). Malarial proteins 
have been already characterized by using this system (Carter et al., 2000, Eckstein-
Ludwig et al., 2003; Nessler et al., 2004).  As a second approach, the Xenopus laevis 
oocyte expression system was chosen for a further and independent characterization 
of pfcha.  For this purpose, the redesigned pfcha was cloned in the Xenopus oocyte 
vector pSP64T such that it was embedded in the sequence coding for the 
untranslated region of the ß-globin gene to enhance the expression. The pfcha 
fragment contained at its 3´end the hemagglutin epitope and contained at the 5’ end 
just before the starting codon a Kozac sequence to enhance expression.  
 
3.3.1 pfcha mediates Ca2+/H+ exchange 
 
To investigate the ability of PfCHA to exchange Ca2+ and protons, the uptake 
of 45Ca2+ into oocytes incubated was measured at different pH values. At each pH, 
uptake in cRNApfcha injected oocytes was compared to control oocytes. As shown in 
Fig. 3.7a, there is a pH-dependent uptake of 45Ca2+ in pfcha expressing oocytes 
whereas in the control oocytes there is no pH-dependent uptake. The uptake 
increased with the pH: the highest 45Ca2+ uptake in pfcha expressing oocytes occured 
when incubated in Ringer solution at pH 8.5. The uptake at pH 8.5 was at least four 
times higher than of the control oocytes. At pH of 6.5, there was almost no difference 
in 45Ca2+ uptake between pfcha expressing oocytes and control oocytes. The rate of 
45Ca2+ uptake at pH 8.5 was linear over 60min (Fig. 3.7b). 
 
If pfcha is a calcium proton exchanger, one would expect protons to leave the 
cell while Ca2+ is being taken up. To test this, an experiment was designed to 
estimate the external pH. To do so, oocytes were incubated in microvolumes of a 
weakly buffered Ringer solution dyed with the pH indicator Phenol-red. By doing so, 
even small variations in the external pH can be detected (Jaisser et al., 1993). As 
expected the solution acidified for a pH of 8.1 to 7.3 when incubated with pfcha 
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expressing oocytes for 60 min. In contrast no pH shift was observed in the control 
oocytes where the pH remained the same i.e. pH 8.1 (Fig. 3.8).   
To investigate if pfcha mediated protons extrusion changes intracellular pH 
homeostasis, the internal pH was measured by using double-barrelled electrodes 
which measured simultaneously the intracellular pH and the membrane potential. 
There was no significant difference in the internal pH measured between pfcha 
expressing oocytes and control oocytes when incubated in Ringer solution at pH 7.5. 
The internal pH measured for the pfcha expressing oocytes and the control oocytes 
was 7.45 ± 0.01 and 7.42 ± 0.02 respectively (Tab. 3.1). This is probably due to the 
high buffer capacity of the oocytes. 
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Fig 3.7a: pH-dependent 45Ca2+ uptake of pfcha expressing oocytes (█) and control oocytes (█). 
Oocytes were investigated 3 days post RNA injection. For each pH, 10 water injected oocytes and 
10 cRNApfcha injected oocytes were separately incubated in 500 µl of Ringer solution containing 10 
µCi/ml of 45Ca2+ at the given pH for 1 h. After incubation the oocytes were thoroughly washed three 
times with a large volume of ice-cold Ringer medium. Each individual oocyte was subsequently 
lysed for 30 min with 200 µl of 5% SDS, before addition of 2.5 ml of scintillation fluid. The 
radioactivity of the solution was measured in a Beckman LS6000IC scintillation counter. 45Ca2+ 
uptake was normalized to that obtained for control oocytes at pH 6.5  
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Fig 3.7b: Time course uptake of 45Ca2+ uptake at pH 8.5 in pfcha expressing (o) oocytes and 
control oocytes (●). Experiment was performed 3 days after injection of cRNApfcha and water. For each 
time point, 10 water injected oocytes and 10 cRNApfcha injected oocytes were separately incubated in 
500 µl of a Ringer solution at pH 8.5 containing 10 µCi/ml of 45Ca2+. After incubation the oocytes were 
thoroughly washed three times with large volumes of ice-cold Ringer medium. Each individual oocyte 
was subsequently placed into a separate scintillation vial, dissolved for 30 min with 200 µl of 5% SDS, 
before addition of 2.5 ml scintillation fluid, and the solution radioactivity was counted in a Beckman 
LS6000IC scintillation counter. Black circles represent water injected oocytes, open circles cRNApfcha 
injected oocytes. Results are the mean of three independent experiments. 45Ca2+ uptake was 
normalized to that obtained for control oocytes at time point 2 min. 
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Fig. 3.8a: The expression of pfcha in the oocytes results in the acidification of the extracellular 
medium. Experiment was done 3 day after injection of cRNApfcha and water. Oocytes injected with 
cRNA or RNAse free water (negative control) were placed under mineral oil in a 0.5-1.0µl droplet of 
Red phenol-dyed Ringer solution, pH 8.1. This picture was taken after 60 min. The pH of the 
surrounding solution of oocytes was approximately 7.3 for the cRNApfcha injected oocytes and 
approximately pH 8.1 for the control oocytes when compared to pH standards. 
 
 
 To further characterize PfCHA and because it showed a calcium proton 
exchange activity, we wanted to know if this exchange is bidirectional. For this 
purpose, pfcha expressing oocytes and control oocytes were loaded with high 
amounts of radioactive calcium and the calcium efflux was measured at an external 
pH of 7.5. After 20min of incubation, the intracellular radioactive Ca2+ did not 
significantly change (Fig. 3.8b). This implies that PfCHA could not transport out Ca2+ 
out of the oocytes, under the experimental conditions. On the contrary, this 
experiment further supports the 45Ca2+ uptake activity of PfCHA because the PfCHA 
containing oocytes were able to accumulate more 45Ca2+ during preloading. 
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Fig. 3.8b: 45Ca2+ efflux for pfcha expressing oocytes (█) and control oocytes (█). 20 cRNApfcha and 20 
control oocytes were loaded with radioactive calcium. They were separately incubated in 1ml of Ringer 
solution containing 50 µl/ml of 45Ca2+ for 3h. After incubation, the oocytes were thoroughly washed 
three times with a large volume of ice-cold Ringer medium. 10 oocytes from each batch were 
individually lysed with 200 µl of 5% SDS, before addition of 2.5 ml of scintillation fluid. The radioactivity 
of the solution was measured in a Beckman LS6000IC scintillation counter. The remaining oocytes 
were separately incubated in Ringer solution for 20min and then treated as the previous oocytes.  
 
 
 
3.3.2 PfCHA is electrogenic 
Exchangers can be electrogenic or electroneutral depending in the electrical balance 
of the charge species across the membrane. Few calcium antiporters have been so 
far studied but the existence of an electrogenic calcium antiporter has been already 
proposed (Zimniak and Barnes, 1980). To investigate the electrogenicity of PfCHA, 
the membrane potential were measured using double-barrelled electrodes. As shown 
in Tab. 3.1, pfcha expressing oocytes have a more positive membrane potential of – 
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30 ± 2 mVas compared to the control oocytes which have a membrane potential of -
50 ± 3 mV. 
 
Tab. 3.1: Internal pH (pHi) and membrane potential of pfcha expressing and control oocytes. 
Measurements were done 3 days after injection of oocytes incubated in Ringer solution at pH 7.5. 
Data are means ± SEM from n independent experiments. * no significant difference, P>0.05.  
 
 
 pHi Vm 
           mV 
Control 7.42 ± 0,02 (3)* -50 ± 3 (3) 
pfcha 7.45 ± 0,01 (6)* - 29 ± 2 (6) 
 
 
3.3.3 The 45Ca2+ uptake can be inhibited 
 
Next we investigated if pfcha expressed in the oocytes was inhibitable. To do so, 
several compounds were tested: Lanthanum, La3+, a known competitive inhibitor of 
Ca2+ transporter; two potent known Na2+/Ca2+ exchanger inhibitors KB-R7983 and 
SEA-0400; and Verapamil, a L-type Ca2+ channel blocker. For the experiments, 
oocytes were incubated in Ringer solution supplemented with the compounds and 
the 45Ca2+ uptake was measured as described in Material and Methods. 50µM 
verapamil and 1mM La3+ were able to almost completely inhibit 45Ca2+ uptake with the 
amount of 45Ca2+ uptake taken up being similar in pfcha expressing oocytes and 
control oocytes (Fig. 3.9). 4µM KB-R7943 was able to inhibit 45Ca2+ uptake into pfcha 
expressing oocytes by 50% whereas 1µM SEA-0400 had no effect on the uptake.  
Several antimalarials were tested in the same way to investigate if PfCHA is a drug 
target. Neither chloroquine nor artemisinin and quinine were able to inhibit the 45Ca2+ 
uptake in the pfcha expressing oocytes under the conditions tested (Fig. 3.10). 
Because KB-R7943 showed an inhibition activity on the 45Ca2+ uptake in oocytes, its 
cytotoxic activity on the parasite was determined. An IC50-value of 1.707µM and 1.85 
µM was found for the chloroquine sensitive strain HB3 and the chloroquine resistant 
strain Dd2, respectively (Fig. 3.11). 
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Fig 3.9: 45Ca2+ uptake in pfcha expressing oocytes (█) and control oocytes (█) in presence of different 
inhibitors. For each inhibitor, 10 water injected oocytes and 10 cRNApfcha injected oocytes were 
separately preincubated in Ringer solution (pH 7.5) containing the inhibitor for 15 min. They were then 
separately incubated in 500 µl of Ringer solution containing 10 µCi/ml of 45Ca2+ and the inhibitor for 1 
h. After incubation the oocytes were thoroughly washed three times with 100 ml of ice-cold Ringer 
medium. Each individual oocyte was subsequently dissolved for 30 min with 200 µl of 5% SDS, before 
addition of 2.5 ml of scintillation fluid, and the radioactivity of the solution was counted in a Beckman 
LS6000IC scintillation counter. * Significant difference in relative (45Ca2+)
 
uptake (P-value < 0.01) 
between the cRNApfcha injected oocytes in the absence of inhibitor and those in presence of inhibitors. 
The assay was normalized to control oocytes in the absence of any compound. 
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Fig. 3.10: 45Ca2+ uptake in pfcha expressing oocytes (█) and control oocytes (█) in presence of 
different antimalarial drugs. For each drug, 10 water injected oocytes and 10 cRNApfcha injected 
oocytes were separately preincubated in Ringer solution (pH 7.5) containing the antimalarial during 15 
min. They were then separately incubated in 500µl of a Ringer solution containing 10µCi/ml of 45Ca2+ 
and the antimalarial for 1 h. After incubation the oocytes were thoroughly washed three times with 100 
ml of the ice-cold Ringer medium. Each individual oocyte was lysed for 30 min with 200 µl of 5% SDS, 
before addition of 2.5 ml of scintillation fluid, and the radioactivity was counted in a Beckman 
LS6000IC scintillation counter. The values were normalized to control oocytes in the absence of 
compounds. 
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Fig. 3.11: Dose response curve of the CQS strain HB3 (A) and the CQR strain Dd2 (B) incubated 
with different concentrations of the Na+/Ca2+ inhibitor KB-R7943. Percentage of growth inhibition is 
shown. IC50-values are 1.7 10-6 M and 1.8 10-6 M for HB3 and Dd2 respectively. 
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4. DISCUSSION 
 
With the underlying motivation of characterizing the putative Plasmodium 
falciparum calcium proton antiporter PfCHA, we have cloned, expressed pfcha in S. 
cerevisiae and in Xenopus oocytes. Our results indicate that PfCHA transports 
calcium against protons in Xenopus oocytes. In S. cerevisiae, this transport activity 
was found to be moderate in our study. 
 
PfCHA shares a number of conserved residues with other Ca2+/H+ exchangers 
and has an overall predicted membrane topology of 11 transmembrane domains 
consistent with other transporters within the calcium hydrogen exchanger family 
(Cunningham and Fink, 1996, Hirschi et al., 1996, Ueoka-Nakanishi et al., 1999). 
Regions determined to be of functional importance in previous studies are also found 
in pfcha. For example we have identified an acidic amino acid motif within a region 
between the transmembrane domain M6 and M7  that has been shown to be 
important for the binding of Ca2+ (Fig. 3.2) (Pittman et al., 2002, Pittman et al., 2002). 
This acidic motif is predicted to be located in the inside loop, though the predicted 
location varied depending on the hydropathy plot programme used. This predicted 
location is different to the other CAX proteins where this motif is in the outside loop. 
The presence of the motif in the outside loop is conceivable if we consider that the 
transport of calcium is directed into the vacuole. PfCHA possesses an extra acidic 
amino acid motif at its N-terminus. This could be a calcium binding domain, which 
may regulate PfCHA exchange activity as similar domains act to regulate exchange 
activity in the cardiac sarcolemmal Na+/Ca2+ exchanger (Matsuoka and Hilgemann, 
1992, Levitsky et al., 1994). 
In Plasmodium falciparum, pfcha is a single copy gene which is expressed 
throughout the asexual life cycle but its expression is significantly elevated during the 
trophozoite to the schizont stage (Fig. 4.1) (Bozdech et al., 2003). Calcium levels in 
the parasite increase during its development and this correlation with the PfCHA 
expression suggests that PfCHA may be a key component in the calcium dependent 
processes during maturation of the parasite.  
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Fig. 4.1 Expression levels of 
PfCHA determined by glass slide 
microarray. Blue plot: averaged 
smoothed normalized log base (2) 
of Cy5/Cy3 for PfCHA grey plot: 
averaged normalized log base (2) 
of Cy5/Cy3 for PfCHA. Source: 
Derisi (Plasmodb.org) 
 
 
 
 
 
Given the sequence features of PfCHA suggesting a calcium hydrogen 
antiporter, we were pleased that this putative function was further supported by our 
experiments performed in Xenopus oocytes. Although the X. laevis oocyte is 
endogenously equipped with a host of ion channels, transport systems and 
receptors, it has proven to be an excellent heterologuous expression system for the 
investigation and characterization of countless transport proteins and receptors. 
Xenopus oocytes are also suited to study developmental biology questions, 
intracellular signalling cascades and biochemical pathways. Fortunately, 
heterologuously expressed transporters can be distinguished from the endogenous 
ones (Weber, 1999). This makes the oocytes a suitable model to investigate 
transport process on a cellular level. The recent functional characterization of the 
malaria chloroquine resistance transporter PfCRT (Nessler et al., 2004) and the 
previous characterization of two malaria Ca2+ transporters (Eckstein-Ludwig et al., 
2003; Krishna et al., 2001) have confirmed that X. laevis oocytes are a valuable tool 
for heterologuous assay of malarial transport proteins. These calcium transporters 
were found to be calcium ATPases and so far, no calcium hydrogen antiporter has 
been identified. 
We have used this Xenopus system to express PfCHA and measure 45Ca2+ 
uptake in the oocytes. Having no antibody against PfCHA, we could only check the 
expression by using a HA-tag fused to the C terminus of PfCHA. The expression of 
PfCHA was unobservable using western analysis with an anti-HA antibody (data not 
Hours 
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shown), although sequencing of the plasmid confirmed that the HA sequence was 
correct and in frame. The quality of the anti-HA antibody itself is undoubted as it 
could recognize another HA-tag protein, expressed in yeast, which we used as 
control. One reason for the failure to detect the HA-tag is that it may have been 
excised and degraded during the processing of PfCHA.  
Nevertheless our functional characterization of PfCHA in Xenopus oocytes 
suggests that PfCHA is a calcium proton antiporter. This conclusion is supported by 
the 45Ca2+ uptake experiments, the pH and the membrane potential measurements, 
as well as the inhibition studies on PfCHA.  Pfcha expressing oocytes were able to 
transport 45Ca against protons in a pH-dependent manner (Fig. 3.7a). Uptake is at 
least four times higher in pfcha expressing oocytes in comparison with the control 
oocytes. These data are consistent with other studies of labelled Ca2+ of 
calcium/cation exchangers (Ca2+/Na+) where the uptake was between 3 to 18 fold 
higher in expressing oocytes (Sigel et al., 1988). The uptake of 45Ca2+ was linear with 
time for pfcha expressing oocytes, feature which is similar to other transporters 
expressed in Xenopus oocytes (Carter et al., 2000). Moreover, the 45Ca2+ uptake of 
pfcha expressing oocytes is coupled to proton extrusions to the extracellular milieu. 
Although external solution pH measurement gives only a qualitative estimation and 
the protocol is technically challenging, one can clearly see a difference in pH 
between the external solution of the pfcha expressing oocytes and the control 
oocytes (Fig. 3.7b). However, this extrusion of protons is not supported by 
measurements of the cytoplasmic pH (Tab 3.1). There was no difference in the pHi 
between the pfcha expressing oocytes and the control oocytes. One reason could be 
that the pH of the solution in which the oocytes were incubated (pH 7.5) was not high 
enough to drive a noticeable extrusion of protons in the extracellular milieu. Another 
reason could be that the buffer capacity of the oocyte was able to compensate for the 
extrusion of protons.  
PfCHA can be inhibited. LaCl3, a calcium competitor, was able to totally inhibit 
the 45Ca2+ uptake by pfcha expressing oocytes as it has been reported elsewhere for 
heterologuous calcium transporters in Xenopus oocytes. KB-R7943, a specific 
inhibitor of Na+/Ca2+ exchangers was also able to inhibit the 45Ca2+ uptake by 50%. 
These evidences support the fact that the uptake of 45Ca2+ in pfcha expressing 
oocytes is specific and related to PfCHA. The fact that KB-R7943 moderately inhibits 
the growth in vitro of Plasmodium falciparum is interesting. Although we can not 
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exclude an unspecific effect of KB-R7943, its IC50-value in culture is comparable to 
the inhibiting value in the oocyte (Fig. 3.9, 3.11). This may imply that the target of KB-
R7943 in the oocyte and in the parasite is the same. In other terms, PfCHA could be 
the target of KB-R7943 in the parasite.   
PfCHA expressing oocytes revealed a change in a basic physiological 
parameter, the membrane potential (Vm). They exhibit a high resting Vm whereas the 
control oocytes have a resting membrane potential similar to values found in other 
studies (Nessler et al., 2004). We cannot exclude the possibility that endogenous 
transporters, such as a not selective cationic conductance, were activated in pfcha 
expressing oocytes, as we found in other study (Nessler et al., 2004), which explain 
the more positive Vm of pfcha expressing oocytes. Selectively, the influx of Ca2+ may 
account for the change in Vm. 
 
In contrast to the calcium hydrogen antiport activity of PfCHA observed in 
Xenopus oocyte, the antiport activity was moderate in S. cerevisiae. We have found 
that PfCHA could only weakly complement the Ca2+ growth defect of yeast strains 
deficient in Ca2+/H+ antiporter (Fig. 3.5). This weak complementation has also been 
reported for other genes from the CAX family. Shigaki et al. found that AtHCX1, a 
Arabidopsis CAX-like gene was not able to complement yeast defects in vacuolar 
Ca2+ sequestration, and ZmHCX1 the monocot CAX-like gene could not strongly 
complement the Ca2+ growth defect (Shigaki and Hirschi, 2000). The inability of 
PfCHA to complement yeast mutants defective in vacuolar Ca2+ transport could be 
due to several reasons, including mislocalisation of PfCHA in yeast, post-translational 
modifications of PfCHA and inhibiting by an N-terminal autoinhibition. 
In our results, confocal fluorescence microscopy and Western analysis (Fig. 
3.4a,b) of subcellular fractions suggest a vacuolar localization of PfCHA. The 
localization of a green VCAX1 in vacuoles of transgenic tobacco has been published 
(Ueoka-Nakanishi et al., 2000). However, the transport of integral membrane proteins 
to the yeast vacuole seems to occur by default (Nothwehr and Stevens, 1994). 
Conceivably, the high expression levels of PfCHA may result in it being targeted to 
the vacuole but in a non functional form. We do believe that at least some of the 
PfCHA is correctly localised to the vacuole in a functional form because we did 
observe a moderate calcium hydrogen antiporter activity (Fig. 3.5). 
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The second potential reason could be that PfCHA may require post-
translational modifications or regulation to efficiently transport Ca2+ into the vacuole. 
Yeast may thus lack the necessary processing factors to activate a PfCHA-
dependent vacuolar Ca2+ transport. Or, in the opposite, processing of PfCHA in yeast 
can result in an inactive form of it, e.g. an N-terminal glycosylation of PfCHA.  
PfCHA calcium hydrogen antiport activity could be modulated by binding of 
suppressors or activators to a regulatory domain. For example in yeast, VCX1 
appears to be negatively regulated at the post-translational level by the 
calcium/calmodulin-dependent phosphatase calcineurin (Cunningham and Fink, 
1996).  
The third potential reason for the moderate activity of pfcha expressing 
oocytes may be due to an autoinhibitory mechanism in PfCHA. Indeed a mechanism 
of N-terminal autoinhibition CAX1 has been reported in the Arabidopsis (Pittman et 
al., 2002, Pittman et al., 2002). Deletions of the first 10, 20, 30 amino acid at the N-
terminus resulted in a protein that now could complement the Ca2+ sensitivity of the 
yeast strain K667, full length CAX1 failed to do so.  We believe that this is the case 
with PfCHA because the N-terminus of PfCHA is more similar to AtCAX1 than it is to 
VCX1 (Fig. 3.1).  
  
 In summary, we have shown that PfCHA has a calcium hydrogen exchange 
activity in Xenopus oocytes and a moderate exchange activity in S. cerevisiae. The  
antiport activity in the oocytes was inhibitable by known Ca2+ inhibitors. We believe 
that PfCHA could be a potential drug target and further studies are needed to 
investigate this. Knock out experiments of pfcha and determination of the subcellular 
localisation of PfCHA in the parasite are important future steps. In the yeast system, 
the regulatory domains of the PfCHA could be evaluated by site directed 
mutagenesis and deletion/insertion experiments.  
 
 
 
 
 
 
 
Summary 
 
 81 
SUMMARY 
 
Despite substantial efforts to control the spread of malaria, this infectious 
disease is still a major global health problem as chemotherapy of malaria parasites is 
limited by established drug resistance and lack of novel affordable treatment options. 
To combat malaria, identification and characterization of essential genes are needed. 
Although the calcium metabolism is very important in the life of P. falciparum, little is 
known about the genes which regulate the transport of calcium. With the release of 
the P. falciparum genome, a putative calcium hydrogen antiporter has been 
identified. To understand the role of this gene in the calcium metabolism of P. 
falciparum and to evaluate it as a drug target, we describe here the functional 
characterization by the heterologuous expression of this putative calcium hydrogen 
antiporter in Xenopus oocytes and in a S. cerevisiae strain which is deficient for the 
yeast vacuolar calcium hydrogen antiporter VCX1.  
The putative 441-residue protein, which we designate PfCHA, is predicted to 
contain 11 membrane-spanning segments and is related to the calcium exchanger 
family. Expression of pfcha in Xenopus oocytes resulted in a higher and pH-
dependent uptake of pfcha expressing oocytes, in comparison with control oocytes. 
External pH estimation showed that the calcium uptake was coupled to extrusion of 
protons out of the oocytes. In other experiments, we found that PfCHA has an 
antiport activity which is linear with time, unidirectional and electrogenic. Moreover 
PfCHA was inhibitable by La3+, a calcium transporter competitor, and was moderately 
inhibited by a sodium calcium exchanger inhibitor KB-R7943. This inhibitor showed 
also a moderate inhibition on parasite growth in culture. In contrast to the Xenopus 
oocytes, expression of pfcha in yeasts mutants defective in the Ca2+ transport 
resulted in a weakly complementat ion of the calcium tolerance. Our subcellular 
experiments suggested that PfCHA was localized to the yeast vacuole. These results 
confirm that PfCHA is a calcium hydrogen antiporter and we speculate that PfCHA 
could be a potential drug target. Further studies are needed to localize it in the 
parasite and to evaluate it as a drug target. 
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ZUSAMMENFASSUNG 
Trotz erheblicher Bemühungen die Verbreitung von Malaria einzuschränken, 
stellt diese infektiöse Krankheit immer noch ein globales Gesundheitsproblem dar, da 
die Chemotherapie der Malariaparasiten durch Medikamentenresistenz erschwert 
wird und es einen Mangel an neuen erschwinglichen Behandlungsmethoden gibt. 
Um Malaria bekämpfen zu können, ist die Identizifierung und die Charakterisierung 
von essentiellen Genen erforderlich. Gegenstand der vorliegenden Arbeit ist deshalb 
der Calciummetabolismus, welcher bedeutend für den Lebenszyklus von P. 
falciparum ist. Bislang ist allerdings wenig über die beteiligten Gene bekannt, die den 
Transport von Calcium regulieren. Nach der Vervollständigung des Genoms von P. 
falciparum, wurde ein mutmaßlicher Ca2+/H+-Austauscher identifiziert. Um die Rolle 
dieses Gens im Calciummetabolismus von P. falciparum verstehen zu können und 
um zu untersuchen, ob dieser Transporter als möglicher Angriffspunkt für ein 
Medikament dienen könnte, wurde der mutmaßliche Ca2+/H+-Austauscher zur 
funktionellen Charakterisierung in den Oozyten von X. laevis sowie in S. cerevisiae 
exprimiert. Der verwendete Stamm von S. cerevisiae weist einen defekten 
vakuolären Ca2+/H+-Austauscher (VCX1) auf.    
Das 441 Aminosäuren umfassende Protein, welches als PfCHA bezeichnet 
wird, weist 11 vorhergesagte Transmembran-Domänen auf und gehört zur Familie 
der Ca2+/H+-Austauscher. Im Vergleich mit Kontroll-Oozyten, rief die Expression von 
pfcha in Oozyten von X. laevis einen höheren und pH-abhängigen Einstrom von 
45Ca2+ hervor. Externe pH Messungen zeigten, dass die Calcium-Aufnahme in 
Oozyten an eine Extrusion von Protonen gekoppelt ist. Weitere Experimente zeigten, 
dass PfCHA eine Antiportaktivität aufweist, die linear zur Zeit, elektrogen und 
unidirektional verläuft. Außerdem konnte PfCHA sowohl durch La3+, ein 
Calciumtransporter-Inhibitor als auch durch den Na+/Ca2+-Austauscher-Inhibitor KB-
R7943 gehemmt werden, wobei die Hemmung durch KB-R7943 schwächer war. KB-
R7943 zeigte auch eine mittelstarke Inhibierung des Parasitenwachstums in der 
Kultur. Im Gegensatz zu pfcha-exprimierenden Oozyten von X. laevis ergab die 
Expression von pfcha in Hefemutanten, deren vakuolärer Ca2+/H+-Austauscher 
defekt ist, nur eine schwache Komplementierung der Calciumtoleranz. Weitere 
subzelluläre Experimente deuteten darauf hin, dass PfCHA in der Membran vom 
Hefevakuolen lokalisiert ist.  
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Die in der vorliegenden Arbeit gewonnenen Resultate bestätigen, dass PfCHA 
ein Ca2+/H+-Austauscher ist und es kann darüber spekuliert werden, dass PfCHA ein 
mögliches Angriffsziel für Medikamente sein könnte. Weitere Studien sind notwendig, 
um PfCHA im Parasiten zu lokalisieren und es als mögliches Medikamentenziel 
bewerten zu können. 
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